Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleMinireview

Alternative Splicing in the Cytochrome P450 Superfamily Expands Protein Diversity to Augment Gene Function and Redirect Human Drug Metabolism

Andrew J. Annalora, Craig B. Marcus and Patrick L. Iversen
Drug Metabolism and Disposition April 2017, 45 (4) 375-389; DOI: https://doi.org/10.1124/dmd.116.073254
Andrew J. Annalora
Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig B. Marcus
Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick L. Iversen
Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

The human genome encodes 57 cytochrome P450 genes, whose enzyme products metabolize hundreds of drugs, thousands of xenobiotics, and unknown numbers of endogenous compounds, including steroids, retinoids, and eicosanoids. Indeed, P450 genes are the first line of defense against daily environmental chemical challenges in a manner that parallels the immune system. Several National Institutes of Health databases, including PubMed, AceView, and Ensembl, were queried to establish a comprehensive analysis of the full human P450 transcriptome. This review describes a remarkable diversification of the 57 human P450 genes, which may be alternatively processed into nearly 1000 distinct mRNA transcripts to shape an individual’s P450 proteome. Important P450 splice variants from families 1A, 1B, 2C, 2D, 3A, 4F, 19A, and 24A have now been documented, with some displaying alternative subcellular distribution or catalytic function directly linked to a disease pathology. The expansion of P450 transcript diversity involves tissue-specific splicing factors, transformation-sensitive alternate splicing, trans-splicing between gene transcripts, single-nucleotide polymorphisms, and epigenetic regulation of alternate splicing. Homeostatic regulation of variant P450 expression is influenced also by nuclear receptor signaling, suppression of nonsense-mediated decay or premature termination codons, mitochondrial dysfunction, or host infection. This review focuses on emergent aspects of the adaptive gene-splicing process, which when viewed through the lens of P450–nuclear receptor gene interactions, resembles a primitive immune-like system that can rapidly monitor, respond, and diversify to acclimate to fluctuations in endo-xenobiotic exposure. Insights gained from this review should aid future drug discovery and improve therapeutic management of personalized drug regimens.

Introduction

Mapping the human genome sequence was completed in 2001 (Lander et al., 2001), helping to usher in the “postgenomic era” of personalized medicine. Over a decade later, however, the promise of pharmacogenomics (PGx) has yet to fully materialize, and the composition of the human genome remains enigmatic, as numerous questions linger concerning the complexity of its content and organization. For example, how can a genome with only 22,000 genes produce a proteome with over 200,000 distinct proteins? While transcription is a relatively well understood phenomenon, the mechanisms involved in regulating alternative precursor or unprocessed messenger RNA (pre-mRNA) splicing, the driving force behind both transcriptome and proteome expansion, remains less appreciated. The ability to link a single gene to its full suite of RNA transcripts and polypeptide products will improve our ability to assess the functional nature of its role in both physiologic and pathologic conditions (La Cognata et al., 2014). The spectrum of alternate splicing mechanisms underlying the expansion of the proteome involves the use of seven main splicing types, as previously described (Blencowe, 2006; Roy et al., 2013). The molecular basis for these mechanisms is complex and beyond the scope of this review; however, a brief description of the phenomenon and its key players is provided in the supplemental materials (see Supplemental Fig. 1). Here we will focus primarily on the spectrum of phenotypic outcomes induced by alternative transcript splicing, in order to highlight the array of splice-sensitive features operating in the cytochrome P450 (P450) superfamily, a collection of 57 human genes that coordinate the metabolism of both drugs and endoxenobiotics.

This work focuses new attention on the biologic impact of alternative P450 gene splicing, an underappreciated component of phase I drug metabolism that may complicate or disrupt personalized approaches to medicine. Precision medicine, therefore, through the universal application of genetics, still faces many challenges beyond cost, ethical considerations, and the need for additional, whole genome sequences. Multiple resources have now been developed, in addition to the Human Genome Project, to address these challenges, including: the Hapmap Project, which enables single-nucleotide polymorphism (SNP) arrays for >100,000 SNPs; the 1000 Genomes Project; the ENCODE project for noncoding RNAs; and the National Human Genome Research Institute (NHGRI) genome-wide association studies (GWAS) catalog. GWAS have now identified two P450s that represent a biomarker for disease or a drug-response phenotype, including: 1) a CYP2C8 association with bisphosphonate-related osteonecrosis of the jaw in multiple myeloma (Sarasquete et al., 2008); and 2) a CYP2C19 association with clopidogrel interindividual variation as an antiplatelet drug (Shuldiner et al., 2009). Aside from showing strong associations, few pharmacogenetic biomarkers of this sort have successfully transitioned from discovery to clinical practice (Carr et al., 2014). Many GWAS studies have failed to provide prognostic value because they are not designed to evaluate how variant gene expression is influenced by both cellular and environmental splicing factors. In this regard, we feel a new appreciation is needed for the complexity of alternative splicing. For not only is the world of both coding and noncoding RNA more diverse and more complex than we could have imagined even a decade ago, it is teeming with untold amounts of RNA “dark matter” and other relics of the RNA world, whose structure and function must be fully appreciated and classified before a new guiding orthodoxy for “individualized medicine” can be safely conceived (St. Laurent et al., 2014; Cowie et al., 2015).

Meta-Analysis of Alternative Gene Splicing in the Cytochrome P450 Superfamily

Alternative splicing regulated by tissue-specific factors is a means of adapting to physiologic demands. Tissue-specific splice variants may arise from tissue-specific promoter elements (Wiemann et al., 2005) or tissue-specific–splicing regulatory elements (Black, 2000). Exon and intron definition requires interaction of discrete cis-elements (exonic-splicing enhancers, exonic-splicing silencers, intronic splicing silencers, and intronic-splicing enhancers) with tissue-specific, trans-acting, splicing regulatory factors. In this way the same pre-mRNA transcript can be processed into tissue-specific, alternately spliced forms (Wang and Burge, 2008). The cytochrome P450 superfamily of genes is well studied from many perspectives (Guengerich, 2013; Johnson and Stout, 2013; Pikuleva and Waterman, 2013). As of late 2015, PubMed listed over 23,790 citations referencing human P450 genes (according to GeneCards.org), with much of this work being focused on tissue-specific expression or catalytic function of individual, reference forms. Alternative splicing of P450s has also been well studied for more than two decades; however, the structural and functional diversity of P450 splice variants, and their relationship to human health and disease, remains poorly understood. A summary of known P450 splice variants linked to human disease is presented in Table 1. Reports from groups attempting to synthesize a global view of alternative P450 splicing, and its relevance to our understanding of human metabolism in the context of PGx or personalized medicine, are exceedingly rare (Nelson et al., 2004; Turman et al., 2006).

View this table:
  • View inline
  • View popup
TABLE 1 

Pathologies associated with P450 splice variants

Our review has led us to conclude that personalized approaches to medicine whose sole basis is GWAS may be misleading, in that they fail to account for variability in compensatory splicing mechanisms, which can modulate the expression of some highly penetrant mutations. This phenomenon is exemplified by ontogenetic regulatory factors that can mask the physiologic impact of genetic variations among developmentally regulated P450 genes (Hines and McCarver, 2002). To expand on this concept, and explore the array of alternative splicing products that serve as an improved platform for predicting disease whose basis is the functional genome, we annotated all of the known human P450 splice variants currently listed in the NCBI’s PubMed, AceView, and Ensembl databases (Thierry-Mieg and Thierry-Mieg, 2006; Cunningham et al., 2015) as of late 2015. From this computational meta-analysis, we found that the 57 human P450 genes produce a P450 “transcriptome cloud” composed of at least 965 unique mRNA transcripts (Table 2). This number represents all known reference (or wild-type) and variant P450 mRNAs, including some with retained introns, premature termination codons (PTCs), and those subject to nonsense-mediated decay (NMD); we also included several experimentally derived transcripts described in PubMed-listed citations (identified by searching CYP* or P450 splice variant or alternative CYP* or P450 splicing) that were not represented in the AceView or Ensembl databases.

View this table:
  • View inline
  • View popup
TABLE 2 

Summary of human P450 splice variants

Our results approximate that the average P450 gene encodes nearly 20 unique mRNA transcripts, capable of yielding both reference and splice-variant proteins, and an ensemble of noncoding RNA molecules. Over 53% of these transcripts (515) are predicted to express viable proteins, on the basis of the most stringent expression criteria used by both the AceView and Ensembl databases (Table 2). Subsequent analysis of the GeneCards.org website revealed that the 57 human P450s are associated with over 48,384 SNPs, approximating to roughly 850 mutations per P450 gene (Stelzer et al., 2011). Although most P450s fall within this general range of genetic variation, some, including CYPs 2C19, 5A1, 19A1, and 39A1, express more than twice as many SNPs as the average, suggesting the accumulation process is nonrandom (Table 2). The total number of diseases associated with each of the 57 human genes (1057) was also calculated using the MalaCards Human Disease Database (Rappaport et al., 2014). P450 families 1 (203) and 2 (413) account for over half of the total disease associations, whereas orphan P450s CYP20A1 (1) and CYP39A1 (2) are associated with the fewest.

A side-by-side, radar-plots comparison of the total number of alternative P450 splice variants and SNPs for each of the 57 human P450 genes is shown in Fig. 1. Pharmacologically relevant drug targets, such as CYP2C9, CYP2D6, CYP3A5, CYP11A1, and CYP19A1, are among the most highly spliced P450 genes, the majority of which are also subject to trans-splicing events. Although differences in gene organization or cell-specific selection pressure may play a role in this phenomenon, our observations suggest that drug-dosing guidelines derived from knowledge of a patient’s individual P450 transcriptome may be far superior to those resulting from genotyping alone, as SNP approaches may tend to overstate (or oversimplify) the biologic influence of a point mutation on gene function. Although computational studies indicate that 85% of all human mRNA comes from a single major transcript (Gonzàlez-Porta et al., 2013), the P450 superfamily of genes is highly diverse at the genomic level, making it uniquely sensitive to alternate splicing events that alter the biologic output of both genetic and epigenetic signaling cascades. Nuclear receptors are now recognized for their role in mediating global gene-splicing events (Auboeuf et al., 2005), and an improved framework for how this process functions to regulate drug metabolism appears to be in order, one that can potentially recontextualize the utility and complexity of the convoluted metabolic crosstalk network that underlies the 48 nuclear receptor (NR) signaling pathways operating in humans (Meyer, 2007; Tralau and Luch, 2013).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Comparative analysis of the complete human cytochrome P450 transcriptome and the total number of single-nucleotide polymorphisms. Radar plot comparison of the total number of (A) human P450 transcript variants and (B) SNPs for each of the 57 human cytochrome P450 genes are shown, on the basis of a meta-analysis of information of the NCBI’s Ensembl, PubMed, and AceView databases and the GeneCards.org website. Total transcript variants for individual P450 genes identified in this study are superimposed (in pink) over the current number listed in the AceView database alone (in purple). The expansion in variant numbers we identified highlights the challenge of predicting interindividual variability in polymorphic P450 gene splicing, predicated on existing transcript databases. Radar plot comparison of the total human SNPs associated (as reported by GeneCards.org) revealed CYP5A1 (or thromboxane synthase 1) as the most polymorphic P450 gene (5274), with CYPs 2C19 (2467), 7B1 (3400), 19A1 (2178), and 39A1 (2129) showing higher rates of polymorphism than the average P450 gene (∼850 mutations per gene). (C) Bar graph representation of alternative P450 transcript-to-SNP ratios for each gene is shown at the bottom. CYP2E1, with 24 transcript variants and the lowest number of SNPs (33), displays the highest alternative transcript-to-SNP ratio (0.73) among human P450 genes. CYPs 21A2 (0.33), 27B1 (0.15), and CYP2D6 (0.11) also skew above normal for this ratio (∼0.05 alternative transcripts per SNP). Improved understanding of the SNP-based mechanisms that alter P450 gene splicing will facilitate the identification of novel SNP biomarkers that are predictive of drug interactions and human disease.

Furthermore, drug metabolizing P450s of families 1–4 have traditionally been considered more polymorphic than P450s that metabolize endogenous, cholesterol-based substrates and are assumed to be more sensitive to SNP-based modulation of alternative splicing (Lewiñska et al., 2013). On the basis of our analysis, it does appear that that the majority of steroid-metabolizing P450s, including CYP17A1 (91 SNPs) and CYP21A2 (173 SNPs), are among the least polymorphic P450 genes. As described above, mutations in these P450 enzymes are closely linked to congenital defects such as pseudohermaphroditism and adrenal hyperplasia (Yamaguchi et al., 1998; Doleschall et al., 2014), and SNPs may be less well tolerated in these systems owing to their central role in the production of sex hormones, progestins, and corticoids. In contrast, the 35 drug-metabolizing P450s that compose P450 families 1–4 in humans average over 700 SNPs per isoform, and the 25,659 total polymorphisms in this group represent over 53% of the total P450 SNP population. Although CYP2C9 (1422 SNPs), CYP2C18 (1230 SNPs), and CYP2C19 (2467) are the most polymorphic drug-metabolizing P450s, they are considerably less polymorphic than genes like CYP5A1 (5274 SNPs), which metabolizes prostaglandins, and CYP7B1 (3400 SNPs), which converts cholesterol to bile acids. CYP5A1 is also known as thromboxane synthase (TBXAS1), a functionally distinct P450 that catalyzes molecular rearrangements of its substrates (Hecker and Ullrich, 1989). CYP5A1-based SNPs represent more than 10% of all P450 polymorphisms in humans and are recognized for altering tissue-specific splicing in blood and lung cells (Wang et al., 1994), and for promoting alternative exon 12 inclusion to promote cerebrovascular disease (Kimouli et al., 2009). CYP2E1 displayed the lowest number of SNPs (33) and the highest alternative transcript-to-SNP ratio (0.73) among human P450 genes (see Fig. 1). CYPs 21A2 (0.33), 27B1 (0.15), and CYP2D6 (0.11) also skew above normal P450 superfamily genes with respect to the average alternative transcript-to-SNP ratio of 0.05. Improved understanding of how key SNPs interact with the environment to alter individual P450 gene-splicing outcomes, therefore, could be very helpful in improving the predictive power of personalized medicine predicated on genetic screening.

Therefore, some SNPs alter gene function by modulating alternative splicing events, but the total number in a population may be irrelevant from an evolutionary perspective if they do not manifest in alternative phenotypes. Furthermore, it is intriguing that several steroid hormone-metabolizing P450s, including CYP7B1 (3400 SNPs), CYP19A1 (2178 SNPs), and CYP39A1 (2129 SNPs) display disproportionate amounts of polymorphisms compared with all other human P450s, reiterating the possibility that SNP expansion among P450 genes is neither random nor predictable on the basis of the tissue-specific expression or substrate-selectivity of an individual P450. What may be more important with respect to the accumulation of SNPs is their ability to be silenced or masked via alternative or trans-splicing paradigms that render them invisible or inconsequential to the natural selection process. The defective nature of a P450-related SNP may depend on its ability to manipulate the P450 transcriptome; therefore, improved understanding of how key mutations alter P450 gene-splicing outcomes may be critical to addressing the goal of precision medicine in the post-genomic era.

Tissue-Specific Alternative Splicing of Cytochrome P450 Genes: Historical Perspective

During the late 1980s and early 1990s, several groups began to appreciate the possibility that differential RNA splicing might serve as an additional mode for regulating P450 function. In 1987, the first P450 splice variant for hepatic P450-1, later renamed CYP2C8, was reported (Okino et al., 1987). Over the next decade, several examples of alternate splicing were documented for several human P450s, including lung CYP4F2 (Nhamburo et al., 1990) and liver CYP2B6 (Miles et al., 1989; Yamano et al., 1989) and CYP2A7 (Ding et al., 1995). In the latter case, a tissue-specific, alternative splicing effect was documented, in which a 44-kDa CYP2A7-AS splice variant (compared with the 49-kDa wild-type protein) found only in 20% of liver samples was the dominant protein expressed in human skin fibroblasts. Just two years later, a similar pattern of alternative splicing behavior was documented for CYP2C18, which selectively encodes splice variants skipping different combinations of exons 4, 5, 6, and 7 in the epidermis (Zaphiropoulos, 1997). Circular RNA transcripts synthesized from the donor and acceptor sites from the skipped segments of exons 4­–7 were also documented and, although the epigenetic function of this class of RNA remains unclear (Salzman et al., 2012), they were easily detected on the basis of their increased stability (Zaphiropoulos, 1997). Important studies that focused on environmentally responsive, alternative P450 splicing among xenobiotic-metabolizing P450s of the rat 2A family were also conducted during this era (Desrochers et al., 1996).

By 1999, the CYP2C18 alternative-splicing story became even more complex when it was discovered that CYP2C18 and CYP2C19, which cluster on chromosome 10q24 with CYP2C9, also participate in tissue-specific, trans-splicing events, among the three genes (Zaphiropoulos, 1999). Over the next decade, cell-specific splicing factors responsible for directing the complex, post-transcriptional gene assembly of P450s (and other genes) were identified (Wang and Burge, 2008). However, the physiologic importance of the more unusual P450 splice variant and chimeric forms remains unclear, particularly with respect to how their variable, tissue-specific expression alters interindividual sensitivity to hormones, pharmaceuticals, and xenobiotics.

As discussed above, a single P450 gene can be translated into multiple, variant protein sequences, solely on the basis of tissue-specific differences in the expression of key gene-splicing machinery [e.g., small nuclear RNA (snRNAs)]. Several alternately spliced CYP1A1 transcripts identified in human brain tissues exemplify this phenomenon, as well as the concept of tissue-specific spliceosome activity (Bauer et al., 2007). Inducible CYP1A1 is constitutively expressed in the brain, where it is localized to neurons in the cortex, cerebellum, and hippocampus. An 87-bp deletion in exon 6 is observed in the brain-specific CYP1A1 form, but not in liver (Chinta et al., 2005). Human brain tissues expressing the Δexon6-CYP1A1 variant do not express wild-type CYP1A1 and they metabolize known substrates [e.g., benzoxy-resorufin and benzo(a)pyrene (BP)] at different rates than wild-type enzyme (Kommaddi et al., 2007). Furthermore, cells expressing wild-type CYP1A1 generate DNA adducts via the formation of reactive 3-OH-BP products, whereas cells expressing the Δexon6-CYP1A1 variant in brain do not (Kommaddi et al., 2007).

On the basis of the structural analysis of CYP1A1 in Fig. 2 (derived from PDB: 4I8V; Walsh et al., 2013), tissue-specific, alternative splicing of exon 6 may reshape the size and polarity of the CYP1A1 substrate access channel to alter substrate recruitment and recognition processes and redox-partner binding interactions. Exon 6 of CYP1A1 appears to be organized for “plug and play” utilization in the brain, where targeted skipping does not compromise the global P450 fold but alters substrate specificity for a spectrum of endogenous substrates, including testosterone. This tissue-specific exon 6 usage of CYP1A1 is complemented by a similar pattern of alternative exon 2 usage found in human endothelial cells, leukocytes, and tumor cells (Leung et al., 2005, Bauer et al., 2007). As shown in Fig. 2, targeted skipping of an 84-bp cryptic intron in exon 2 of CYP1A1 produces a catalytically unique splice variant with diminished estradiol metabolism that localizes to the nucleus and mitochondria rather than the endoplasmic reticulum (ER) (Leung et al., 2005). The added diversity in both structure/function and subcellular distribution observed for exon 2-modified, CYP1A1 splice variants found both in normal and tumor tissues remains enigmatic and denotes a higher level of structural plasticity with respect to tertiary structure than might be currently appreciated or expected from classic structural studies of wild-type P450 forms (Johnson and Stout, 2013).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Tissue-specific and transformation-sensitive alternative splicing of CYP1A1 in humans. CYP1A1 is inducible in virtually every tissue of the body; however, a brain-specific CYP1A1 splice variant has been identified that preferentially skips exon 6 (Kommaddi et al., 2007). This shortened form of the enzyme is spectrally active but does not metabolize benzo(a)pyrene to toxic metabolites in brain. Structural analysis of the CYP1A1 crystal structure (PDB: 4I8V) indicates that removal of exon 6 (in yellow ribbon) would: 1) expand the opening of the pw2b substrate access channel, 2) reshape the ligand binding pocket by altering the β1-4 sheet, and 3) alter the redox partner binding surface via elimination of the K′ helix. A similar pattern of tissue-specific, alternative exon 2 usage in CYP1A1 has been reported in tumor cells (Leung et al., 2005). Ovarian cancer cells skip an 84-bp cryptic intron in exon 2 of CYP1A1 but remain in-frame to produce a catalytically unique splice variant with diminished estradiol metabolism that localizes to the nucleus and mitochondria, rather than the ER. Cryptic intron removal in exon 2 eliminates 28-amino-acid residues among helices E, F, and the E–F loop (shown in transparent gold ribbon), which putatively expands the opening of the pw3 substrate access channels located above the heme center and helix I.

Perhaps the most dramatic, and mutually exclusive, example of tissue-specific, alternate-exon usage in P450s was documented for CYP4F3, which can be expressed as two distinct splice variant forms (CYP4F3A and CYP4F3B). These two CYP4F3 isoforms differ only by their variable usage of exons 3 and 4, which encode distinct portions of the active site and substrate access channel, allowing them to fine-tune substrate specificity (Christmas et al., 1999, 2001). CYP4F3A is expressed in blood and bone marrow myeloid cells, selectively expresses cassette exon 4 (and not 3), and has low affinity for leukotriene B(4) (LTB4). In contrast, CYP4F3B, expressed exclusively in the liver and kidney, encodes exon 3 (and not 4) and has high affinity for LTB4, in addition to other functional differences. The highly concerted, tissue-specific splicing of CYP4F3 exemplifies the functional utility of the modular P450 gene platform, one that allows cells to sample a continuum of gene products as dictated by tissue-specific physiologic stress conditions.

However, it should also be clearly noted that not all P450 genes are divided into an equal number of coding and noncoding regions, which suggests that the accumulation of introns may be an adaptive and ongoing process. For example, the CYP1B1 gene, which encodes a P450 enzyme that metabolizes both xenobiotics and endogenous substrates, contains only two coding exons (Supplemental Fig. 2) and, therefore, is not subject to the same patterns of alternative splicing as other CYP1 family members 1A1 and 1A2, which have six coding exons (Stoilov et al., 1998). In this regard, the most well studied splice variants of CYP1B1 all represent severe truncations or deletion mutants, not exon skipping (Tanwar et al., 2009), and CYP1B1 retains an unusual, elongated C-terminus, further distinguishing it from other human P450 forms. The CYP1B1 gene is also uniquely located on chromosome 2 at locus 2p21–22, which in humans is derived from an ancient fusion of chimpanzee chromosomes 2a and 2b (Faiq et al., 2014). It is difficult to speculate why the CYP1B1 gene is organized so differently from closely related CYP1A genes located on chromosome 15. However, observations linking a common set of nuclear proteins to both the alternative splicing process and NMD seem to imply that expansion of gene complexity may be related more to the rate at which a given mRNA transcript is processed by the spliceosome and ribosome, rather than other evolutionary factors (Lejeune and Maquat, 2005; McGlincey and Smith, 2009). Ultimately, the adaptive forces driving the modular organization of genes into variable numbers of introns and exons remain a point of speculation. However, a gene’s intronic complexity clearly influences its sensitivity to alternate-splicing events and the domain swapping paradigm. The tissue-specific use of alternative promoters and non-AUG translation start-sites also is facilitated by this type of hidden gene complexity, which allows discrimination among a set of well defined exons and poorly defined pseudoexons.

In 2005, a truncated, CYP24A1 splice variant incapable of metabolizing hormonal forms of vitamin D was identified in the human macrophage (Ren et al., 2005). CYP24A1 is the prototypical mitochondrial P450 responsible for the side-chain cleavage of the vitamin D hormone and it possesses a mitochondrial localization sequence in the first 30 residues of its N-terminus (Annalora et al., 2004). The CYP24A1 splice variant found in activated macrophage (CYP24A1-SV1) lacks 153 N-terminal residues encoded by exons 1 and 2, and gains eight residues preceding the content from exon 3, via a partial insertion of intron 2. CYP24A1-SV1 is thought to function as a soluble variant that disrupts normal vitamin D hormone metabolism via the sequestration of key intermediates from both wild-type CYP27B1 and CYP24A1 (Ren et al., 2005). In this regard, the CYP24A1-SV1 variant may promote a discrete pattern of vitamin D hormone accumulation in the macrophage, and potentially other tissues such as the intestine, where vitamin D hormonal leakage from irritated cells is thought to contribute to the burst of extracellular hormone observed in inflammatory disorders like Crohn’s disease (Abreu et al., 2004; Mangin et al., 2014). A structural analysis of the CYP24A1-SV1 variant is shown in Fig. 3 (on the basis of PDB: 3K9V; Annalora et al., 2010), and it highlights how the targeted loss of N-terminal residues from exons 1 and 2 could reconfigure the membrane-binding surface and substrate access channel to alter the catalytic properties of wild-type CYP24A1.

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Alternative-splicing of the human CYP24A1 gene: tissue- and tumor-specific exons 1, 2, and 10 inclusion. CYP24A1 is a mitochondrial P450 composed of 11 coding exons that metabolizes the vitamin D hormone to regulate its role in calcium homeostasis, cell growth, and immunomodulation. Alternatively spliced transcript variants have been identified for this gene, including a CYP24A1 splice variant (CYP24sv) specifically expressed in macrophage (Ren et al., 2005), which skips exons 1 and 2. The 372-amino-acid variant protein (∼43 kDa) lacks the N-terminus, helices A′, A, B, and B′ and portions of the β1 sheet but probably retains the ability to bind heme and substrate in some capacity. Ren and coauthors concluded that CYP24sv represents a cytosolic variant with dominant-negative function that quarantines 25-hydroxyvitamin D3 and other hormonal forms of vitamin D, slowing the rate of their metabolism in the mitochondria or endoplasmic reticulum. Structural analysis of CYP24A1 (PDB: 3K9V) suggests that CYP24sv’s unique N-terminus, derived from intron 2 (shown in green), reshapes the pw2a substrate access channel and provides contacts for sealing the ligand binding pocket via interactions with helices F–G and the β1 and β4 sheets systems. It is notable that exons 1 and 2 exclusion in CYP24A1 is exacerbated in human tumors of the breast and colon, where N-terminally truncated splice variants of approximately 40, 42, and 44 kDa have been identified (Fischer et al., 2009a; Horváth et al., 2010; Scheible et al., 2014). An additional, prostate cancer-related, splice variant of CYP24A1 that cleanly skips exon 10 has also been described (Horvath et al., 2010; Muindi et al., 2007). Exon 10 encodes much of the protein’s proximal surface, including the β1–3 sheet, meander region, CYS loop, and portions of the L-helix involved in heme-thiolate bond formation. Variants lacking exon 10 may express defects in heme and redox partner binding, giving rise to an alternative dominant negative form that may retain membrane-binding features; loss of exon 10 could also refine the alternative functions of cytosolic splice variants lacking exons 1 and 2.

Interestingly, the orphan P450 CYP27C1, a close relative of CYP24A1, encodes a 372-residue wild-type protein that resembles the CYP24A1-SV1. CYP27C1 lacks a prototypical N-terminus and initiates coding in the middle of canonical helix C, at a position analogous to the alternative start site used by CYP24A1-SV1 (Ren et al., 2005). CYP27C1 is expressed in liver, kidney, pancreas, and several other tissues, and remained an orphan for over a decade (Wu et al., 2006), until recently, when it was shown to mediate the conversion of vitamin A1 (all-trans retinol) into vitamin A2 (all-trans 3,4-dehydroretinal) in cell culture (Kramlinger et al., 2016). It is intriguing that CYP27C1 may represent a codified version of the more soluble P450 isotype recapitulated by CYP24-SV1, and that this transition may mediate a general switch between vitamin A and vitamin D substrate specificity. Improved knowledge of CYP27C1 structure/function could help to unravel some of the complexity associated with the variant P450 regulation, particularly for variants subject to atypical subcellular trafficking events.

Therefore, although increasingly common in the literature, the functional significance of many tissue-specific P450 variants remains elusive. CYP2C8, for example, is constitutively expressed in the liver at 5–7% of the total tissue P450, has more than 20 known alternately spliced variants, and is a breast cancer biomarker owing to its high expression in mammary tumors (Knüpfer et al., 2004). Bimodal targeting to both mitochondria and ER have been reported for CYP2C8 and several other P450s, including CYP1A1, 1B1, 2B1, 2E1, and 2D6. Although it is clear that alternative splicing directs this process in some tissues, proteolytic cleavage of N-terminal targeting sequences can also produce this effect (Bajpai et al., 2014). One 2C8 variant (variant 3; ∼44 kDa) with an alternative N-terminus is targeted to the mitochondria, where it may contribute to oxidative stress (Bajpai et al., 2014). The catalytic competency of these untethered variants remains a topic of intense debate, as it is often difficult to assign an orphan function to a variant protein that has lost selectivity to the gene’s prototypical substrates. A review of P450 splice variants subject to alternate subcellular trafficking is shown in Supplemental Table 1. Computational analysis from the AceView database (Thierry-Mieg and Thierry-Mieg, 2006) indicate that some P450 variants may be targeted to the nucleus, peroxisome, plasma membrane, or vacuole compartments, in addition to classic targets in the ER, mitochondria, or cytoplasm. This analysis hints that P450 splice variants, including tumor-specific forms, may be performing an array of unrecognized functions, including diverse roles at the cell surface and beyond, which are rarely considered (Eliasson and Kenna, 1996; Stenstedt et al., 2012).

Transformation-Sensitive Alternative Splicing in the Cytochrome P450 Superfamily

This transformation-specific, P450 splicing phenomenon was first documented in 1996 for the prototype P450, CYP19A1 (or aromatase), which facilitates estrogen biosynthesis via three successive hydroxylations of the androgen A ring and displays a unique pattern of exon 1 (and cryptic intron) usage in human breast tumor cells and tissues (Zhou et al., 1996). A similar pattern of CYP19A1 exon 1 variant expression also has been documented in sheep, cattle, and rabbit, suggesting this paradigm is not exclusive to humans or transformed-tissue types (Vanselow et al., 1999; Bouraïma et al., 2001). More recently, it was determined that CYP19A1’s exon 5 also is defined poorly and subject to both splicing mutations and physiologic alternative splicing events (Pepe et al., 2007). Skipping of exon 5, which encodes complete α-helices D and E in CYP19A1, eliminates prototypical P450 aromatase activity in both steroidogenic and nonsteroidogenic tissues (Lin et al., 2007; Pepe et al., 2007). These observations suggest a tissue-specific, regulatory mechanism for aromatization on the basis of alternative exon 5 inclusion in humans. A structural analysis of this CYP19A1 splice variant is depicted in Supplemental Fig. 3 (on the basis of PDB: 3S79; Ghosh et al., 2012). In aromatase, exon 5 skipping naturally suppresses androgen metabolism by redefining the determinants of substrate recognition. While transfection studies suggest CYP19A1 variant proteins are encoded and not subject to NMD, their ability to alter the safety and efficacy of several CYP19A1 (aromatase) inhibitor drugs [e.g., Arimidex (anastrozole), Aromasin (exemestane), Femara (letrozole), and Teslac (testolactone)] remains unclear (Hadfield and Newman, 2012) and an area of active investigation (Liu et al., 2013a; Liu et al., 2016).

The tissue-specific, alternative start-site usage of CYP24A1, discussed above, appears to be exacerbated in several human transcript variants in which an array of truncated splice variants of approximately 40, 42, and 44 kDa have been identified with similar N-terminal modifications (Fischer et al., 2009a; Horváth et al., 2010; Scheible et al., 2014). An additional, cancer-related, splice variant of CYP24A1 that cleanly skips exon 10 has also been documented (Muindi et al., 2007; Horvath et al., 2010). In CYP24A1, exon 10 encodes much of the protein’s proximal surface, including the CYS loop, and a portion of helix L involved in heme-thiolate bond formation and adrenodoxin recognition (shown in Fig. 3). Although the function of this cancer-specific variant remains unknown, it may have reduced ability to bind heme and redox partners compared with truncated variants (skipping exons 1 and 2), and thus may represent an alternative, dominant-negative variant also capable of modulating vitamin D hormone metabolism and metabolite trafficking at the plasma membrane level. As discussed previously, the cellular mechanisms regulating CYP24A1 alternative spicing in the macrophage remains unclear, although cell-specific variations in splicing factors (e.g., heterogeneous ribonuclear protein A1) are thought to be responsible (Ren et al., 2005). A more complex pattern of “transformation-sensitive” alternative CYP24A1 gene splicing also has been documented in human tumors of the prostate (Muindi et al., 2007), breast (Fischer et al., 2009a; Scheible et al., 2014), and colon (Horváth et al., 2010; Peng et al., 2012). It is thought that whereas intronic SNPs may facilitate the alternate splicing pattern seen for CYP24A1 in prostate cancer cells, vitamin D hormone exposure also putatively alters splicing via discrete interactions among the vitamin D receptor (VDR) and nuclear-splicing factors like the heterogeneous nuclear ribonucleoprotein C (hnRNPC; Zhou et al; 2015). Tumor cells overexpressing CYP24A1, therefore, may not retain sufficient hormone to activate the VDR properly, disrupting normal gene-splicing events needed to properly transduce the hormone’s immunogenic, prodifferentiation properties. CYP24A1 splice variants have now been documented among multiple human breast tumor cell lines (e.g., MCF-7 and MCF-10) and in both healthy and malignant breast tumor tissues. In benign tissue, wild-type CYP24A1 (56 kDa) was the only isoform present. In malignant tissues, three splice variants (40, 42, and 44 kDa) were expressed, similar to cultured MCF-7 breast tumor cells that express the 42- and 44-kDa variants (Fischer et al., 2009a; Scheible et al., 2014). A similar pattern of transformation-sensitive splicing is seen in human colon cancer tissues, where the histological grade and the gender of the patient modulates the formation of the three detectable CYP24A1 splice variants (Horváth et al., 2010). Peng and coworkers (2012) further refined our understanding of this process in the colon by demonstrating that cell- or tissue-specific splicing patterns were suppressed by parathyroid hormone signaling, but only in the absence of the vitamin D hormone, which may be the master regulator of both CYP24A1 gene expression and splicing.

The phenotypic instability exemplified by the CYP24A1 gene in human tumors complicates the therapeutic landscape from which rational drugs for cancer can be conceived (Trump et al., 2006). Epigenetic modification of the CYP24A1 gene and its promoter also may contribute to tissue-specific differences in P450 expression (Johnson et al., 2010). Frontiers in this area of research will likely address the coordinated role that nuclear hormone receptors and epigenetic splicing factors (including noncoding forms of RNA) play in managing both the transcriptome and the epigenome.

It should be noted that the CYP27B1 gene, which is highly related to CYP24A1, was also recognized early as being sensitive to transformation-specific alternative splicing in malignant human glioma cells (Maas et al., 2001). CYP27B1 variant expression has now been documented in tumors of the breast, skin, cervix, kidney, and ovaries (Diesel et al., 2004; Fischer et al., 2007, 2009b; Wu et al., 2007). Tissue-specific CYP27B1 splicing also is common in healthy skin, where a 59-kDa variant with a 3-kDa insertion between exons 2 and 3 and exclusive to skin was observed and linked to the activity of cAMP response element–binding elements (Flanagan et al., 2003). Fluctuations in skin cell density, calcium concentrations, and UV-B light exposure were also shown to affect the splicing process (Seifert et al., 2009). Collectively, these findings help to validate our core hypothesis that alternative gene splicing, dictated by both cellular and environmental factors such as UV light exposure and nutritional status, can alter a patient’s metabolic profile in tissue-, age-, sex-, exposure-, and disease-specific ways that are difficult to predict.

Research focused on CYPs 19A1, 24A1, and 27B1 is among the most comprehensive on transformation-sensitive alternative splicing in human P450s, and the literature is replete with anecdotal reports of alternative P450 splicing among various transformed cell types and tissues. For example, CYP2E1 transcripts that selectively skip exons (2, 2–3, and 2,4,5–5′,6) were identified in lung carcinoma cell lines but not in corresponding lung tumor tissue or liver extracts, where splice variants were found to be noninducible by ethanol exposure (Bauer et al., 2005). The authors noted at the time that none of these splice variants were accounted for in the National Institutes of Health (NIH) AceView database, highlighting the longstanding challenge associated with cataloging splice variant forms derived from cell-specific abnormalities versus those generated from normal, tissue-specific splicing paradigms. Furthermore, several orphan P450s, including CYP1B1, CYP2S1, and CYP2W1 are highly associated with specific human tumor types, making them important prodrug targets for chemoprevention strategies (Stenstedt et al., 2012). Unfortunately, as discussed above, the alternative splicing behavior of orphan P450s is often as poorly understood as are their cryptic functions.

Interestingly, orphan CYP2W1, which is expressed in human tumor types of the colon, is associated almost exclusively with aberrant P450 behavior, including an inverted orientation in the ER membrane, and glycosylation-sensitive trafficking to the plasma membrane (Gomez et al., 2010; Stenstedt et al., 2012). The increased expression of CYP2W1 in tumors is associated with demethylation of a CpG island in the exon 1-intron 1 junction of the gene. How this mechanism relates to the paucity of normal CYP2W1 expression in healthy tissues remains unclear, but it implies that the expression of some specialized P450s may only be invoked under extreme cellular stress, when an alternative P450 activity may be critical for balancing cellular homeostasis. The abnormal expression and trafficking of CYP2W1 to the plasma membrane could promote an autoimmune response as part of its mechanism. A similar autoimmune reaction is associated with aberrant CYP2E1 trafficking in animal tissues treated with halothane (Eliasson and Kenna, 1996). The NIH’s AceView and Ensembl (Cunningham et al., 2015) databases indicate that CYP2W1 encodes at least 11 transcript variants, three of which lack one or more exons and are associated with hepatocellular carcinomas, adenocarcinomas, and neuroblastomas. Nearly 200 of the 965 alternatively spliced P450 transcripts we identified in public database searches were associated with a well-characterized human tumor type. Improved understanding of their tumor-specific cellular roles and the mechanisms regulating their induction should aid in the identification of improved disease biomarkers and P450 variant-specific therapeutic agents.

Trans-Splicing of Cytochrome P450 Gene Chimeras

It is well understood that both transformation-sensitive cellular changes and P450 polymorphisms can alter protein expression in multiple ways that are often difficult to predict from primary sequence analysis alone. This challenge is exacerbated in situations where chimeric P450 genes are created via trans-splicing events among extended (or multiple) pre-mRNA transcripts. Therefore, although mutations in a gene like CYP2C9 are linked to poor metabolism of several drugs, including phenytoin and tolbutamide, the role that alternative or trans-gene splicing plays in manifesting a deleterious CYP2C9-related metabolic phenotype are rarely considered. For example, several CYP2C9 splice variants (CYP2C9sv) have been identified (Ohgiya et al., 1992), including a liver-specific form that skips exon 2 (Ariyoshi et al., 2007). The internally truncated CYP2C9 variant is spectrally active but does not metabolize prototype CYP2C9 substrates. A structural analysis of the CYP2C9 crystal structure (PDB: 4NZ2; Brändén et al., 2014; shown in Supplemental Fig. 4A) hint that removal of exon 2 would reshape portions of the reference protein relative to its membrane-binding surface, substrate access channel, active site, and redox partner binding surface. CYP2C9 is located within a cluster of P450 genes on chromosome 10q24 and is subject to nonrandom, trans-splicing events with neighboring CYPs 2C8, 2C18, and 2C19 in liver and skin, where CYP2C18 exon 1–like sequences were found spliced into different combinations of introns and exons from the CYP2C9 genes (Warner et al., 2001). Common 2C9-related SNPs linked to various metabolic disorders, therefore, may only function to modulate the innate splicing process indirectly. This is particularly true if their coding regions are spliced out of chimeric 2C forms being expressed on an interindividual basis, highlighting another major flaw in GWAS targeting of the components of gene clusters.

The CYP2D gene family also is complex, clustered, and subject to trans-splicing events; it is composed of CYP2D6 and 4 pseudogenes (CYP2D7P1 and 2 and CYP2D8P1 and 2). Alternative splicing of the CYP2D family pre-mRNAs has been detected in human liver, breast, and lung tissue (Huang et al., 1996, 1997), including a highly expressed splice variant that completely skips exon 6. As shown in Supplemental Fig. 4B, analysis of the CYP2D6 crystal structure (PDB: 4WNU: Wang et al., 2015) reveals that exon 6 encodes the complete coding sequence for helix I, and that skipping this important region would dramatically alter protein structure/function by removing key catalytic residues (e.g., Thr-309) and remodeling the distal pocket of the active site. Alternate CYP2D6 exon usage is tissue-selective, and variant forms skipping exon 3 and portions of exon 4 have been documented that alter enzyme function and subcellular localization (Sangar et al., 2010). CYP2D6 polymorphisms are linked to modified enzyme activity and may serve as biomarkers for poorly metabolizing phenotypes sensitive to dose-dependent drug toxicity. Recently it was reported that intronic polymorphisms in CYP2D6*41 individuals (considered intermediate metabolizers) could dramatically increase the expression levels of CYP2D6 variants lacking exon 6 (Toscano et al., 2006). These findings, coupled with the complex organization of the CYP2D gene cluster, indicate that both alternative and trans-splicing mechanisms may underlie the complex genotype-phenotype relationships associated with variable CYP2D6 metabolism in humans, and that CYP2D6 is well organized structurally to exploit both tissue- and transformation-selective splicing mechanisms targeting helices C and D (exon 3) and helix I (exon 6).

The CYP3A gene family (comprising CYPs 3A4, 3A5, 3A7, and 3A43) is also highly complex in humans, with each gene consisting of 13 exons (with ∼71–88% amino acid identity) that cluster on chromosome 7q21–22.1, where the CYP3A43 gene is in a head-to-head orientation with the other three genes (Finta and Zaphiropoulos, 2000). Several chimeric forms of CYP3A mRNAs have been described, in which CYP3A43 exon 1 is joined at CYP3A4 and CYP3A5 canonical splice sites, implying a trans-splicing mechanism that bypasses classic transcriptional control paradigms. In Supplemental Fig. 5A, a structural analysis of CYP3A4 (on the basis of PDB: 4K9T; Sevrioukova and Poulos, 2013) reveals the highly complex segmentation of the CYP3A4 gene into 13 exonic domains, which, as described above, may potentiate rapid translation upon induction (Lejeune and Maquat, 2005; McGlincy and Smith, 2008). Primary amino acid sequence alignments of key CYP3A genes suggest exon 1 may encode distinct transmembrane anchor helices and membrane-binding architecture (Supplemental Fig. 5B), hinting that CYP3A chimeras may encode a spectrum of phenotypes with unique tissue-specific distribution and functionalities. A CYP3A4 trans-splicing variant containing CYP3A43 exon 1, followed by CYP3A4 exons 4–13, has been described; it retains detectable testosterone 6-β-hydroxylase activity despite losing membrane-binding features encoded by exons 2 and 3, comprising helices A′ and A, and portions of the β1-1 sheet (Supplemental Fig. 5C). A CYP3A4 trans-splicing variant containing CYP3A43 exon 1, followed by CYP3A4 exons 7–13, has been studied also, and it displays minimal 6-β-hydroxylase activity (Supplemental Fig. 5D). This story is further complicated by the presence of additional CYP3A pseudogenes (CYP3AP1 and CYP3AP2) in the intergenic regions between CYP3A4, 3A7, and 3A5, where discrete exons from the pseudogenes also have been found trans-spliced into CYP3A7 transcripts (Finta and Zaphiropoulos, 2002). Ultimately, CYP3A4 and CYP3A5 splicing complexity may help to explain how intronic SNPs in CYP3A4*22 patients alter tacrolimus metabolism, without introducing a nonsynonymous mutation to an exon (Elens et al., 2011). The predictive power of GWAS may therefore need to be reconsidered, particularly with respect to the most complex P450 gene families defined by the presence of pseudogenes (e.g., CYP 2C, 2D, 3A, 21A, and 51A families) and trans-splicing mechanisms.

SNP-Sensitive Alternative Splicing in the Cytochrome P450 Superfamily

As discussed above, tissue-specific, alternative and trans-splicing behaviors have now been documented for several important P450 gene families; however, SNPs can destabilize this process in complex ways that are often difficult to predict. SNPs that target cryptic intronic recognition elements or discrete intron/exon splice junction boundaries can alter translation start-and-stop site usage, and the expression ratios among wild-type and variant P450 transcripts. Some P450 SNPs are exceedingly rare, occurring in less than 1% of the population. These rare mutations are linked to congenital defects, including glaucoma (CYP1B1; Stoilov et al., 1998; Tanwar et al., 2009; Sheikh et al., 2014), 17-α hydroxylase deficiency (CYP17A1; Yamaguchi et al., 1998; Costa-Santos et al., 2004; Hwang et al., 2011; Qiao et al., 2011), congenital adrenal hyperplasia (CYP21A2; Robins et al., 2006; Lee, 2013; Szabó et al., 2013; Sharaf et al., 2015), spina bifida (CYP26A1; Rat et al., 2006), focal facial dermal dysplasia (CYP26C1; Slavotinek et al., 2013), and cerebrotendinous xanthomatosis (CYP27A1; Garuti et al., 1996; Verrips et al., 1997; Chen et al., 1998; Tian and Zhang, 2011). Other P450 polymorphisms that alter splicing are associated with neurologic and metabolic diseases, including Parkinson’s disease (CYP2D6, Denson et al., 2005; CYP2J2, Searles Nielsen et al., 2013), hypertension (CYP4A11, Zhang et al., 2013; CYP17A1, Wang et al., 2011), breast cancer (CYP2D6, Huang et al., 1996; CYP19A1, Kristensen et al., 2000;) colon cancer (CYP2W1,Stenstedt et al., 2012), and lung cancer (CYP2D6, Huang et al., 1997; CYP2F1, Tournel et al., 2007). However, the complex etiology of these disorders can make it difficult to interpret the exact role that a P450 SNP might play in the actual onset or progression of a disease. Multiple studies of various intergenic, intronic, and exonic polymorphisms that alter human drug and xenobiotic metabolism have also been reported (CYP1A1, Allorge et al., 2003; CYP2C19, de Morais et al., 1994; Ibeanu et al., 1999; Satyanarayana et al., 2009; Sun et al., 2015; CYP2D6, Toscano et al., 2006; Lu et al., 2013; Wang et al., 2014; CYP3A4, Elens et al., 2011; and CYP3A5, Kuehl et al., 2001; Busi and Cresteil, 2005; Lee et al., 2007; García-Roca et al., 2012). In many cases, the most pharmacologically relevant SNPs are those affecting the innate splicing behavior of a given gene. This observation highlights why knowledge of a patient’s discrete P450 transcriptome is so important when selecting a personalized medicine regimen.

It is now clear that numerous P450-related SNPs are found between genes and exons, or in the 5′ or 3′ untranslated regions of RNA transcripts. Polymorphisms in this class have now been identified for virtually every human P450 isoform, with each having the potential to alter splicing in unique ways in different individuals. For example, the CYP3A5*3 SNP (rs776746, also known as 6986A>G) introduces a mutation in intron 3 that alters normal splicing of exon 4, producing a nonfunctional, truncated CYP3A5 protein that predominates in many Caucasians (Kuehl et al., 2001). Expression of the wild-type CYP3A5*1 protein is highly variable among populations and is linked to an increased sensitivity to salt-induced hypertension. Interestingly, some individuals who are homozygous CYP3A5*3/*3 can express both the truncated variant and properly spliced, wild-type CYP3A5 (Lin et al., 2002). Because the CYP3A5*3 mutation occurs in intron 3, over 100 base pairs upstream from the splice donor site of exon 4, it is unclear how this SNP alters normal recognition of the intron 3-exon 4 junction. Although variations in the expression of ubiquitous splicing factors (e.g., U1 small nucleolar ribonuclear proteins) may account for interindividual variability in recognizing the CYP3A5*3 SNP, there are currently no models to explain how this complex, salt-sensitive splicing phenomenon is being regulated in the kidney. The alternative splicing of CYP3A5 variant exemplifies why SNP-based approaches to personalized medicine are so challenging to implement, when the physiologic impact of a given SNP may be the opposite of what is expected. Computational approaches that consider a patient’s age, genotype, nutrition, and disease status may ultimately be needed to make good predictions concerning the impact of a given SNP on an individual’s transcriptome.

The challenge of addressing SNPs for personalized medicine is further complicated by observations that some xenobiotics, including aminoglycosides and cyclohexamides (Busi and Cresteil, 2005), can alter the proofreading capabilities of the ribosome, allowing inhibition of premature stop codons and translational read-thru of alternate transcripts that may or may not remain in-frame with respect to the reference transcript. Improved knowledge of a patient’s chemical exposure history and epigenetic status, therefore, may become increasingly important when making predictions about food and drug safety. Furthermore, personalized approaches to medicine solely on the basis of SNPs identified via cohort studies or GWAS may be fundamentally flawed and potentially misleading, in that they fail to account for the milieu of compensatory cellular mechanisms that are adept at masking the most deleterious effects of even the most highly penetrant mutations.

Addressing Nontraditional P450 Function and Trafficking Events

Our meta-analysis and review of splice variability within the cytochrome P450 superfamily has revealed an under-appreciated level of alternative transcript expansion and variant protein structural complexity that is poorly addressed by conventional P450 structure/function paradigms. Well studied splice variants from the CYP1A family reveal a sophisticated domain-swapping mechanism that allows for tissue-specific sampling of alternative protein conformational space. Discrete arrays of tissue-specific snRNAs (U1–U9) and ancillary splicing factors can alter the biologic syntax of a gene, thus providing a granular mechanism for this natural phenomenon that is highly responsive to environmental factors, including diet and chemical exposure. In human brain, the alternative splicing of CYP1A1 appears linked to a tissue-specific sensitivity to a reactive P450-product (e.g., 3-hydroxybenzo[a]pyrene; Kommaddi et al., 2007). How this gene-specific sensitivity is transduced and imprinted at the genetic level remains enigmatic, but the cellular microenvironment clearly dictates what hidden structural complexity of a P450 gene may be exploited. This observation helps explain why some P450 variants, like CYP24A1-SV1, which are normally expressed in the immune system, can become major players in tumor cells, where they may elaborate a common emergency function, such as the suppression of vitamin D hormone metabolism. This cellular phenomenon corresponds well with related vitamin D hormone–scavenging strategies, such as the 3-epimerization pathway, which can be induced to modify the vitamin D hormone’s chemical ring structure to limit its efficient catabolism via CYP24A1 (Rhieu et al., 2013). To date the enzyme responsible for the 3-epimerization of the vitamin D hormone remains unknown (Bailey et al., 2013).

New appreciation for the increasingly diverse and complex roles that P450 splice variants play in normal biology should help reinvigorate discussions of P450 gene structure and evolution, particularly with respect to the selective forces that regulate P450 gene duplication and mutation events. Although the origin and expansion of spliceosomal introns remains highly debated (Rogozin et al., 2012; Qu et al., 2014), the intron-exon boundaries of 17 of 18 mammalian P450 families appear to be well conserved across almost 420 million years of evolution, as evidenced by the fugu (pufferfish) genome (Nelson, 2003); only the CYP39 gene is missing from fugu and all known fish. The bulk of P450 structural diversity encoded by the human genome, therefore, likely predates the divergence of tetrapods from ray-finned fish over 420 million years ago. In this regard, brain-selective expression of CYP1A1 variants lacking exon 6 in humans may be no more evolved than tissue-specific expression of CYP19A1 splice variants found in fugu. In each case, the induction of P450 splice variants appears to provide a novel mechanism for modulating steroid hormone pleiotropism among a diverse set of target tissues.

The selective pressures that created the modular framework of the P450 gene, therefore, likely predate the Cambrian explosion 540 million years ago, and lurk somewhere in the history of deuterostome evolution (Nelson, 2003). However, contemporary analyses of P450 splicing mechanisms are needed to help elaborate the relationship between alternative subcellular trafficking and alternative P450 variant function in the mitochondria, nucleus, peroxisome, cytoplasm, or plasma membrane (Supplemental Table 2). Because alternative splicing and alternative start-site usage can generate even greater P450 structural diversity than those predicted to arise from post-translational modifications of intracellular targeting motifs, the mechanisms underlying their emergence and regulation deserve greater attention. For example, if subtle differences in the membrane-binding features of CYP1A1 and CYP1A2 can modulate redox partner recruitment and protein interactions within ordered and disordered regions of the lipid bilayer (Park et al.; 2015), metamorphic structural changes associated with some P450 variants may underlie an even greater array of uncharacterized (and potentially moonlighting) P450 functions (Zhao and Waterman 2011; Lamb and Waterman, 2013).

As the landscape of alternate P450 gene functions continues to expand, the cellular basis for alternatively targeting microsomal P450 forms to the mitochondria (e.g., CYP1A1, CYP1A2, CYP1B1 CYP2B1, CYP2B2, CYP2E1, CYP3A1, and CYP3A2) is still being investigated (Anandatheerthavarada et al., 1997). However, a putative role in modulating destructive, subcellular reactive oxygen species (ROS) production has recently been proposed (Dong et al., 2013). This theory emerges from evidence that the alternative trafficking of the related NADPH:quinone oxidase-1 (NQO1) gene, which limits ROS by preventing semiquinone redox cycling, can protect the mitochondria from stress-induced oxidative damage. P450 variants may potentially play a similar role by redirecting the metabolism of reactive subcellular compounds. However, because P450s can also become uncoupled and directly produce ROS via the release of reactive products (i.e., via uncoupled Fenton-type reactions), further attention to the role of alternative P450 splicing in the modulation of mitochondrial stress and dysfunction seem warranted. In this regard, it is intriguing that many P450 splice variants that undergo alternative trafficking often lack a significant portion of the membrane binding domain and/or substrate-access architecture (typically encoded by exons 1–3), which may expand heme accessibility or the rate of uncoupled ROS production. When paired with observations that alternative splicing is a primary mechanism by which mitochondria alter cellular phenotypes to mitigate environmental stress (Guantes et al., 2015), the recognition of new, nonclassic roles for P450 variants linked to disease seems probable.

In this regard, it is interesting that the consensus sequence (GU-AG) of most RNA splice junctions contains a minimum of two guanine nucleotides, which are highly sensitive to ROS-mediated oxidation. In the presence of radical oxygen, guanine is rapidly converted to 8-oxo-guanine and related metabolites that disrupt normal base pairing and local secondary structure. Formation of 8-oxo-guanine at splice junctions can impede target site recognition by splicing factors (e.g., snRNAs and splicing regulatory-factor proteins) and alter RNA polymerase (Pol) II processivity. Furthermore, because some introns are defined by AU-AC junctions rather than GU-AG junctions, the splicing of these introns may be less sensitive to ROS-mediated events and, therefore, may be subject to a different suite of regulatory-splicing mechanisms. For example, the induction of environmentally responsive genes like adenosine-deaminase could alter the recognition of a prototypical AU-AC junction in a similar way, via adenosine-to-inosine (A-to-I) RNA editing (Solomon et al., 2013). Even mitochondrial genes lacking spliceosomal introns could be affected by this phenomenon, as the discrete dinucleotide sequences that coordinate their autocatalytic, self-splicing events could also be potentially altered by P450-mediated ROS modulation (Zimmerly and Semper, 2015).

Shaping an Improved Roadmap toward Precision Medicine

Because changes in mitochondrial function can alter global alternative splicing events, it is not surprising that both phenomenon are linked to the induction of cellular heterogeneity and human disease pathology progression (Raj and van Oudenaarden, 2008; Hanahan and Weinberg, 2011; Pagliarini et al., 2015). Despite a growing appreciation for the role that alternative splicing plays in promoting phenotypic variability, the identification of genetic polymorphisms linked to disease, which may or may not alter gene-splicing events, remains a core focus of pharmacogenomics. Mutations in single genes have now been identified for over 4000 human diseases, of which 5–15% are the result of SNPs resulting in nonsense mutations (Mort et al., 2008). However, SNPs occur in coding regions of genes with a frequency of approximately 1.5%, and of those, only one-third are expected to result in nonsynonymous mutations and a much smaller number alter pre-mRNA processing, leading to a frequency in change of phenotype of only ∼0.5%. When one considers that humans express almost 50,000 SNPs across the 57 human P450 genes, fewer than 250 may be capable of significantly altering a patient’s metabolic phenotype, an insight we contend may help streamline PGx approaches to personalized medicine (Zhou et al., 2009; Zanger and Schwab, 2013). For example, although CYP2D6 genotyping is no longer recommended in the clinical setting for tamoxifen treatments (Abraham et al., 2010; Wu, 2011; Lum et al., 2013), the FDA still considers CYP2D6 clinically actionable from a PGx perspective for codeine and other drugs (Crews et al., 2014). Unfortunately, over 74 allelic variants of CYP2D6 have already been described, which greatly complicates genetic testing and the clinician’s ability to select the appropriate pharmacotherapy and dose (Zhou, 2009). Fortunately, organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Pharmacogenomics Knowledgebase (PharmGKB) are working to standardize methodologies for PGx data analysis and clinical guidance for specific gene-drug pairings (Caudle et al., 2016). However, CPIC concedes that some rare P450 variants may not be included in genetic tests, and that patients may be assigned “wild-type” genetics by default (Crews et al., 2014). When paired with additional uncertainties regarding P450-specific genotype/phenotype associations and the untold numbers of unclassified SNPs, it becomes clear why accurate genetic screening remains challenging, and only one aspect of the therapeutic decision-making process.

Ultimately, the falling cost and broader availability of pyrosequencing technologies support our call for improved RNA sequence strategies for personalized medicine, as accurate identification of the patient’s functional genome is a crucial component of precision medicine. Although transcriptomic analysis offers superior guidance in the design of personalized therapeutic options, its broad implementation will require technical improvements to sample collection and processing that are also problematic for genomic testing. In this regard, complementary metabolomics approaches directed at variant-specific metabolism may provide more feasible, short-term improvements to PGx screening and precision-based approaches to medicine (Beger et al., 2016). Innovative, gene-directed therapeutic technologies such as splice-altering antisense oligonucleotides and CRISPR/Cas9 genome-editing systems may also become feasible tools for manipulating a patient’s transcriptome to optimize therapeutic outcomes. Key examples of splice-switching technology already being investigated to treat human disease are listed in Supplemental Table 2. In this regard, our group has participated in the development of eteplirsen, the new antisense oligonucleotide drug that received accelerated approval from the FDA for the treatment of Duchenne muscular dystrophy (DMD; Syed, 2016; Niks and Aartsma-Rus, 2017). Eteplirsen’s development evolved from early studies of exon skipping in the murine dystrophin model (Fall et al., 2006; Fletcher et al., 2007; Adams et al., 2007; Mitrpant et al., 2009), a canine model of DMD (McClorey et al., 2006b), and in human muscle explants (McClorey et al., 2006a). Our group has also employed exon-skipping oligomers to refine the immune response–mediated gene expression of CD45 protein-tyrosine phosphatase in a murine anthrax model (Panchal et al., 2009; Mourich and Iversen, 2009), of interleukin-10 in an Ebola virus lethal-challenge mouse model (Panchal et al., 2014) and of CTLA-4 in a murine model of autoimmune diabetes (Mourich et al., 2014). We hypothesize that similar splice-altering technology may be useful in redirecting the function of drug metabolizing P450s like CYP3A4 (Arora and Iversen, 2001), whose metabolism of drugs like tamoxifen is linked to genotoxicity (Mahadevan et al., 2006). As our appreciation for transcriptome expansion and the mechanisms of alternative P450 gene-splicing evolve, new therapeutic gene-editing options will probably emerge that could scarcely be predicted using genetic testing alone.

In summary, the human cytochrome P450 family transcriptome contains over 965 different variant forms (Table 2), many with common structural features sensitive to alternative splicing events that expand P450 protein diversity. The transcription and processing of P450 gene transcripts is complex and coordinately regulated within the nucleus by multiple factors, including NR signaling via environmental sensors like the peroxisome proliferator–activated receptors (PPARs) PPARγ and PPARα, which interact with the PGC-1α transcriptional coactivator to regulate oxidative metabolism and mitochondrial biogenesis (Wu et al., 1999; Monsalve et al., 2000). Multiple steroids, including products of CYPs 1A, 1B, 2A, 2B, 2C, 2D, 3A, 7A, 17A, 19A, 24A1, and 51A metabolism, bind NRs and lead to interactions with NR coregulators through LxxLL or FxxLF motifs that modulate the assembly of the spliceosome complex and pre-mRNA splicing (Auboeuf et al., 2005). The androgen receptor (AR), which binds multiple metabolites of CYPs 2A, 2C, 2D, 3A, 17A, 19A, and 21A, can also directly interact with nucleolar splicing factors (e.g., U5 small nucleolar ribonuclear protein), indicating a receptor-mediated role in transcription that is coupled to pre-mRNA splicing mechanisms (Zhao et al., 2002). Vitamin D receptor activation mediated by metabolites of CYPs 2R, 2J, 3A, 11A, 27A, 24A, and 27B can also alter P450 gene expression and splicing through NR-mediated crosstalk (e.g., PPARs) transduced via interactions with the retinoid X receptor (Matsuda and Kitagishi, 2013), recruitment of the NCoA62/SKIP coactivator complex (Zhang et al., 2003), and discrete interactions with the heterogeneous nuclear ribonucleoprotein C-splicing factor (Zhou et al., 2015). Traditional VDR signaling in the nucleus is further refined by several nontraditional NR functions operating near the plasma membrane that alter gene expression via modulation of key membrane-based paracrine signaling pathways, mediated by agents like Wnt and epidermal growth factor (Larriba et al., 2014). Vitamin A metabolites (or retinoids) of CYPs 1A, 2B, 2C, and 26, signaling through the retinoic acid receptor and retinoid X receptor, are also known to guide the recruitment of SC35 coactivators to regulate the alternate splicing of protein kinase delta (PKCδ) among other pre-mRNAs (Apostolatos et al., 2010). Collectively, these data reveal a novel P450-based mechanism for adaptive transcriptome remodeling, whereby xenobiotics and endogenous substrates, monitored by one of several tissue- or disease-specific “P450 clouds,” are metabolized in a coordinated fashion that harmonize NR signaling cascades with alternative gene expression and splicing events that promote adaptive responses to cell stress or stimuli (Fig. 4).

Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

Endoxenobiotic crosstalk among cytochrome P450 and nuclear receptor genes coordinate alternative splicing and resemble a primitive immune system. Human tissues are subject to exposure from over 400 FDA-approved drugs, >10,000 xenobiotics, and untold numbers of endogenous substrates and their metabolites (x > 100,000). Cytochrome P450 genes participate in phase I detoxification of many of these compounds, including model substrates benzo[a]pyrene (via CYP3A4) and calcifediol (via CYP24A1). P450 genes are classically induced to silence endoxenobiotic signaling through cognate nuclear receptors, which modulate global gene expression and splicing events by “coloring” or modulating the composition of coregulatory factors that comprise both the transcription complex and the spliceosome complex, which ultimately alter the nature of both ribosome assembly and gene expression (Auboeuf et al., 2005). Model substrates are subject to metabolism by a finite population of P450s in a given tissue, however, and because each gene is sensitive to an infinite number of environmentally sensitive, alternative splicing events, each individual may express a unique, tissue-specific “P450 gene cloud” comprising both wild-type (WT) and splice-altered variant forms (e.g., SV1, SV2, etc.). P450 splice variants can: 1) display reduced ability to metabolize model substrates, 2) function as dominant negatives to sequester compounds from metabolism or potentiate basal NR-mediated signaling, or 3) function as a conformationally distinct protein with alternative metabolic function or cellular role. When coupled with existing paradigms of alternate P450 trafficking and membrane-associated cooperativity, an integrated network of crosstalk among 57 P450 and 48 NR genes begins to emerge, as novel P450 metabolites may engage NR signaling pathways in unique ways that reprogram gene splicing and expression to promote cellular homeostasis in the face of endocrine disruption. NR signaling cascades can alter both the transcriptome and epigenome of an individual, providing an elegant feedback mechanisms for adaptation to cellular stress created by unique personal history and disease status.

In conclusion, the human metabolome adapts to substrate burden through the induction of gene transcription, which helps to maintain homeostasis in a well documented pathway guided by NR binding and signaling events. In this respect, the metabolic response to xenobiotics (via P450 induction) is adaptive in a manner reminiscent of the immune response to viral antigen; there is a recognition phase of the chemical by the P450 active site, an activation phase when the chemical (or P450 metabolite) interacts with the NR, and an effector phase in which the coordinated transcription and splicing of P450 transcripts occurs to feedback-modulate NR signaling. The analogy to the immune response is appropriate here in that specific transcript variants are produced in response to a specific chemical stimulus. The ability to tightly control cellular homeostasis via NR-mediated gene expression and alternative splicing implies a high order of sophistication operating in what might be considered a primitive, chemical immune response. Molecules that engage this primitive P450-based immune system transduce transcriptome-wide biologic responses capable of reshaping both the phenotype and “epigenotype” of the cell (via the regulation of both coding and noncoding RNA), allowing for reversible environmental adaptation, as well as imprinting, which in rare cases may persist transgenerationally (Hochberg et al., 2011). Improved knowledge of both the adaptive and maladaptive epigenome remodeling processes induced by xenobiotics may ultimately help reconcile interindividual variability in efficacy and toxicity that plague many FDA-approved drugs. These insights will provide new guidance for developing “individualized” therapeutic strategies more sensitive to a patient’s adaptive transcriptome or functional genome, which as exemplified by P450 superfamily of genes is the ultimate expression of the heritable epigenotype and appears to remain environmentally responsive throughout all phases of the human life cycle.

Acknowledgments

The authors thank Dr. Ronald N. Hines (US-EPA) for his thoughtful comments and suggestions concerning this review.

Authorship Contributions

Participated in research design: Annalora, Iversen, Marcus.

Performed data analysis: Annalora, Iversen.

Wrote or contributed to the writing of the manuscript: Annalora, Iversen, Marcus.

Footnotes

    • Received September 2, 2016.
    • Accepted February 6, 2017.
  • This research was supported by start-up funds from the Office of Research and the College of Agricultural Sciences at Oregon State University (Corvallis, OR) awarded to Drs. Marcus and Iversen.

  • dx.doi.org/10.1124/dmd.116.073254.

  • ↵Embedded ImageThis article has supplemental material available at dmd.aspetjournals.org.

Abbreviations

BP
benzo(a)pyrene
ER
endoplasmic reticulum
GWAS
genome-wide association studies
NMD
nonsense-mediated decay
NR
nuclear receptor
P450
cytochrome P450
PGx
pharmacogenomics
PPAR
peroxisome proliferator–activated receptors
pre-mRNA
precursor or unprocessed messenger RNA
ROS
reactive oxygen species
SNP
single-nucleotide polymorphism
snRNA
small nuclear RNA
VDR
vitamin D receptor
  • Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Abraham JE,
    2. Maranian MJ,
    3. Driver KE,
    4. Platte R,
    5. Kalmyrzaev B,
    6. Baynes C,
    7. Luccarini C,
    8. Shah M,
    9. Ingle S,
    10. Greenberg D, et al.
    (2010) CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 12:R64–R75.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Abreu MT,
    2. Kantorovich V,
    3. Vasiliauskas EA,
    4. Gruntmanis U,
    5. Matuk R,
    6. Daigle K,
    7. Chen S,
    8. Zehnder D,
    9. Lin YC,
    10. Yang H, et al.
    (2004) Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn’s disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 53:1129–1136.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Adams AM,
    2. Harding PL,
    3. Iversen PL,
    4. Coleman C,
    5. Fletcher S, and
    6. Wilton SD
    (2007) Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol Biol 8:57–65.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Allorge D,
    2. Chevalier D,
    3. Lo-Guidice JM,
    4. Cauffiez C,
    5. Suard F,
    6. Baumann P,
    7. Eap CB, and
    8. Broly F
    (2003) Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol 56:341–344.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Anandatheerthavarada HK,
    2. Addya S,
    3. Dwivedi RS,
    4. Biswas G,
    5. Mullick J, and
    6. Avadhani NG
    (1997) Localization of multiple forms of inducible cytochromes P450 in rat liver mitochondria: immunological characteristics and patterns of xenobiotic substrate metabolism. Arch Biochem Biophys 339:136–150.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Annalora A,
    2. Bobrovnikova-Marjon E,
    3. Serda R,
    4. Lansing L,
    5. Chiu ML,
    6. Pastuszyn A,
    7. Iyer S,
    8. Marcus CB, and
    9. Omdahl JL
    (2004) Rat cytochrome P450C24 (CYP24A1) and the role of F249 in substrate binding and catalytic activity. Arch Biochem Biophys 425:133–146.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Annalora AJ,
    2. Goodin DB,
    3. Hong WX,
    4. Zhang Q,
    5. Johnson EF, and
    6. Stout CD
    (2010) Crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism. J Mol Biol 396:441–451.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Apostolatos H,
    2. Apostolatos A,
    3. Vickers T,
    4. Watson JE,
    5. Song S,
    6. Vale F,
    7. Cooper DR,
    8. Sanchez-Ramos J, and
    9. Patel NA
    (2010) Vitamin A metabolite, all-trans-retinoic acid, mediates alternative splicing of protein kinase C deltaVIII (PKCdeltaVIII) isoform via splicing factor SC35. J Biol Chem 285:25987–25995.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Ariyoshi N,
    2. Shimizu Y,
    3. Kobayashi Y,
    4. Nakamura H,
    5. Nakasa H,
    6. Nakazawa K,
    7. Ishii I, and
    8. Kitada M
    (2007) Identification and partial characterization of a novel CYP2C9 splicing variant encoding a protein lacking eight amino acid residues. Drug Metab Pharmacokinet 22:187–194.
    OpenUrlPubMed
  10. ↵
    1. Arora V and
    2. Iversen PL
    (2001) Redirection of drug metabolism using antisense technology. Curr Opin Mol Ther 3:249–257.
    OpenUrlPubMed
  11. ↵
    1. Auboeuf D,
    2. Dowhan DH,
    3. Dutertre M,
    4. Martin N,
    5. Berget SM, and
    6. O’Malley BW
    (2005) A subset of nuclear receptor coregulators act as coupling proteins during synthesis and maturation of RNA transcripts. Mol Cell Biol 25:5307–5316.
    OpenUrlFREE Full Text
  12. ↵
    1. Bailey D,
    2. Veljkovic K,
    3. Yazdanpanah M, and
    4. Adeli K
    (2013) Analytical measurement and clinical relevance of vitamin D(3) C3-epimer. Clin Biochem 46:190–196.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Bajpai P,
    2. Srinivasan S,
    3. Ghosh J,
    4. Nagy LD,
    5. Wei S,
    6. Guengerich FP, and
    7. Avadhani NG
    (2014) Targeting of splice variants of human cytochrome P450 2C8 (CYP2C8) to mitochondria and their role in arachidonic acid metabolism and respiratory dysfunction. J Biol Chem 289:29614–29630.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Bauer M,
    2. Herbarth O,
    3. Aust G, and
    4. Graebsch C
    (2005) Molecular cloning and expression of novel alternatively spliced cytochrome P450 2E1 mRNAs in humans. Mol Cell Biochem 280:201–207.
    OpenUrlPubMed
  15. ↵
    1. Bauer M,
    2. Herbarth O,
    3. Rudzok S,
    4. Schmücking E,
    5. Müller A,
    6. Aust G, and
    7. Gräbsch C
    (2007) Diversity of common alternative splicing variants of human cytochrome P450 1A1 and their association to carcinogenesis. Int J Oncol 31:211–218.
    OpenUrlPubMed
  16. ↵
    Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, Brennan L, Wishart DS, Oresic M, Hankemeier T et al. for “Precision Medicine and Pharmacometabolomics Task Group”—Metabolomics Society Initiative (2016) Metabolomics enables precision medicine: “a white paper, community perspective”. Metabolomics 12:149.
  17. ↵
    1. Black DL
    (2000) Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology. Cell 103:367–370.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Blencowe BJ
    (2006) Alternative splicing: new insights from global analyses. Cell 126:37–47.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Bouraïma H,
    2. Hanoux V,
    3. Mittre H,
    4. Féral C,
    5. Benhaïm A, and
    6. Leymarie P
    (2001) Expression of the rabbit cytochrome P450 aromatase encoding gene uses alternative tissue-specific promoters. Eur J Biochem 268:4506–4512.
    OpenUrlPubMed
  20. ↵
    1. Brändén G,
    2. Sjögren T,
    3. Schnecke V, and
    4. Xue Y
    (2014) Structure-based ligand design to overcome CYP inhibition in drug discovery projects. Drug Discov Today 19:905–911.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Busi F and
    2. Cresteil T
    (2005) CYP3A5 mRNA degradation by nonsense-mediated mRNA decay. Mol Pharmacol 68:808–815.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Carr DF,
    2. Alfirevic A, and
    3. Pirmohamed M
    (2014) Pharmacogenomics: Current State-of-the-Art. Genes (Basel) 5:430–443.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Caudle KE,
    2. Gammal RS,
    3. Whirl-Carrillo M,
    4. Hoffman JM,
    5. Relling MV, and
    6. Klein TE
    (2016) Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm 73:1977–1985.
    OpenUrlAbstract/FREE Full Text
    1. Chen PH,
    2. Lee KW,
    3. Hsu CC,
    4. Chen JY,
    5. Wang YH,
    6. Chen KK,
    7. Wang HM,
    8. Huang HW, and
    9. Huang B
    (2014) Expression of a splice variant of CYP26B1 in betel quid-related oral cancer. Sci World J 2014:810561.
    OpenUrl
  24. ↵
    1. Chen W,
    2. Kubota S,
    3. Ujike H,
    4. Ishihara T, and
    5. Seyama Y
    (1998) A novel Arg362Ser mutation in the sterol 27-hydroxylase gene (CYP27): its effects on pre-mRNA splicing and enzyme activity. Biochemistry 37:15050–15056.
    OpenUrl
  25. ↵
    1. Chinta SJ,
    2. Kommaddi RP,
    3. Turman CM,
    4. Strobel HW, and
    5. Ravindranath V
    (2005) Constitutive expression and localization of cytochrome P-450 1A1 in rat and human brain: presence of a splice variant form in human brain. J Neurochem 93:724–736.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Christmas P,
    2. Jones JP,
    3. Patten CJ,
    4. Rock DA,
    5. Zheng Y,
    6. Cheng SM,
    7. Weber BM,
    8. Carlesso N,
    9. Scadden DT,
    10. Rettie AE, et al.
    (2001) Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem 276:38166–38172.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Christmas P,
    2. Ursino SR,
    3. Fox JW, and
    4. Soberman RJ
    (1999) Expression of the CYP4F3 gene. tissue-specific splicing and alternative promoters generate high and low K(m) forms of leukotriene B(4) omega-hydroxylase. J Biol Chem 274:21191–21199.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Costa-Santos M,
    2. Kater CE,
    3. Dias EP, and
    4. Auchus RJ
    (2004) Two intronic mutations cause 17-hydroxylase deficiency by disrupting splice acceptor sites: direct demonstration of aberrant splicing and absent enzyme activity by expression of the entire CYP17 gene in HEK-293 cells. J Clin Endocrinol Metab 89:43–48.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Cowie P,
    2. Hay EA, and
    3. MacKenzie A
    (2015) The noncoding human genome and the future of personalised medicine. Expert Rev Mol Med 17:e4.
    OpenUrl
  30. ↵
    1. Cunningham F,
    2. Amode MR,
    3. Barrell D,
    4. Beal K,
    5. Billis K,
    6. Brent S,
    7. Carvalho-Silva D,
    8. Clapham P,
    9. Coates G,
    10. Fitzgerald S, et al.
    (2015) Ensembl 2015. Nucleic Acids Res 43:D662–D669.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Crews KR,
    2. Gaedigk A,
    3. Dunnenberger HM,
    4. Leeder JS,
    5. Klein TE,
    6. Caudle KE,
    7. Haidar CE,
    8. Shen DD,
    9. Callaghan JT,
    10. Sadhasivam S, et al., and Clinical Pharmacogenetics Implementation Consortium
    (2014) Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 95:376–382.
    OpenUrlCrossRefPubMed
  32. ↵
    1. de Morais SMF,
    2. Wilkinson GR,
    3. Blaisdell J,
    4. Nakamura K,
    5. Meyer UA, and
    6. Goldstein JA
    (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–15422.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Denson J,
    2. Wu Y,
    3. Yang W, and
    4. Zhang J
    (2005) Inter-individual variation of several cytochrome P450 2D6 splice variants in human liver. Biochem Biophys Res Commun 330:498–504.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Desrochers M,
    2. Christou M,
    3. Jefcoate C,
    4. Belzil A, and
    5. Anderson A
    (1996) New proteins in the rat CYP2B subfamily: presence in liver microsomes of the constitutive CYP2B3 protein and the phenobarbital-inducible protein product of alternatively spliced CYP2B2 mRNA. Biochem Pharmacol 52:1311–1319.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Diesel B,
    2. Seifert M,
    3. Radermacher J,
    4. Fischer U,
    5. Tilgen W,
    6. Reichrath J, and
    7. Meese E
    (2004) Towards a complete picture of splice variants of the gene for 25-hydroxyvitamin D31α-hydroxylase in brain and skin cancer. J Steroid Biochem Mol Biol 89-90:527–532.
    OpenUrl
  36. ↵
    1. Ding S,
    2. Lake BG,
    3. Friedberg T, and
    4. Wolf CR
    (1995) Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochem J 306:161–166.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Doleschall M,
    2. Szabó JA,
    3. Pázmándi J,
    4. Szilágyi Á,
    5. Koncz K,
    6. Farkas H,
    7. Tóth M,
    8. Igaz P,
    9. Gláz E,
    10. Prohászka Z, et al.
    (2014) Common genetic variants of the human steroid 21-hydroxylase gene (CYP21A2) are related to differences in circulating hormone levels. PLoS One 9:e107244.
    OpenUrl
  38. ↵
    1. Dong H,
    2. Shertzer HG,
    3. Genter MB,
    4. Gonzalez FJ,
    5. Vasiliou V,
    6. Jefcoate C, and
    7. Nebert DW
    (2013) Mitochondrial targeting of mouse NQO1 and CYP1B1 proteins. Biochem Biophys Res Commun 435:727–732.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Elens L,
    2. Bouamar R,
    3. Hesselink DA,
    4. Haufroid V,
    5. van der Heiden IP,
    6. van Gelder T, and
    7. van Schaik RH
    (2011) A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 57:1574–1583.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Eliasson E and
    2. Kenna JG
    (1996) Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 50:573–582.
    OpenUrlAbstract
    1. Elmabsout AA,
    2. Kumawat A,
    3. Saenz-Méndez P,
    4. Krivospitskaya O,
    5. Sävenstrand H,
    6. Olofsson PS,
    7. Eriksson LA,
    8. Strid A,
    9. Valen G,
    10. Törmä H, et al.
    (2012) Cloning and functional studies of a splice variant of CYP26B1 expressed in vascular cells. PLoS One 7:e36839.
    OpenUrlCrossRefPubMed
  41. Erratums. Nature 2001; 411 (6838):720; Nature 2001; 412 (6846):565.
  42. ↵
    1. Faiq MA,
    2. Dada R,
    3. Sharma R,
    4. Saluja D, and
    5. Dada T
    (2014) CYP1B1: a unique gene with unique characteristics. Curr Drug Metab 15:893–914.
    OpenUrl
  43. ↵
    1. Fall AM,
    2. Johnsen R,
    3. Honeyman K,
    4. Iversen P,
    5. Fletcher S, and
    6. Wilton SD
    (2006) Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genet Vaccines Ther 4:3–15.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Finta C and
    2. Zaphiropoulos PG
    (2000) The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 260:13–23.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Finta C and
    2. Zaphiropoulos PG
    (2002) Intergenic mRNA molecules resulting from trans-splicing. J Biol Chem 277:5882–5890.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Fischer D,
    2. Becker S,
    3. Cordes T,
    4. Bücker B,
    5. Diedrich K,
    6. Friedrich M,
    7. Salehin D, and
    8. Thill M
    (2009a) Vitamin D-24-hydroxylase in benign and malignant breast tissue and cell lines. Anticancer Res 29:3641–3645.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Fischer D,
    2. Seifert M,
    3. Becker S,
    4. Ludders D,
    5. Cordes T,
    6. Reichrath J, and
    7. Friedrich M
    (2007) 25-Hydroxyvitamin D3 1alpha-hydroxylase splice variants in breast cell lines MCF-7 and MCF-10. Cancer Genomics Proteomics 4:295–300.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Fischer D,
    2. Thomé M,
    3. Becker S,
    4. Cordes T,
    5. Diedrich K,
    6. Friedrich M, and
    7. Thill M
    (2009b) 25-Hydroxyvitamin D3 1alpha-hydroxylase splice variants in benign and malignant ovarian cell lines and tissue. Anticancer Res 29:3627–3633.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Flanagan JN,
    2. Wang L,
    3. Tangpricha V,
    4. Reichrath J,
    5. Chen TC, and
    6. Holick MF
    (2003) Regulation of the 25-hydroxyvitamin D-1alpha-hydroxylase gene and its splice variant. Recent Results Cancer Res 164:157–167.
    OpenUrlPubMed
  50. ↵
    1. Fletcher S,
    2. Honeyman K,
    3. Fall AM,
    4. Harding PL,
    5. Johnsen RD,
    6. Steinhaus JP,
    7. Moulton HM,
    8. Iversen PL, and
    9. Wilton SD
    (2007) Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 15:1587–1592.
    OpenUrlCrossRefPubMed
  51. ↵
    1. García-Roca P,
    2. Medeiros M,
    3. Reyes H,
    4. Rodríguez-Espino BA,
    5. Alberú J,
    6. Ortiz L,
    7. Vásquez-Perdomo M,
    8. Elizondo G,
    9. Morales-Buenrostro LE,
    10. Mancilla Urrea E, et al.
    (2012) CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing. Arch Med Res 43:283–287.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Garuti R,
    2. Lelli N,
    3. Barozzini M,
    4. Tiozzo R,
    5. Dotti MT,
    6. Federico A,
    7. Ottomano AM,
    8. Croce A,
    9. Bertolini S, and
    10. Calandra S
    (1996) Cerebrotendinous xanthomatosis caused by two new mutations of the sterol-27-hydroxylase gene that disrupt mRNA splicing. J Lipid Res 37:1459–1467.
    OpenUrlAbstract
  53. ↵
    1. Ghosh D,
    2. Lo J,
    3. Morton D,
    4. Valette D,
    5. Xi J,
    6. Griswold J,
    7. Hubbell S,
    8. Egbuta C,
    9. Jiang W,
    10. An J, et al.
    (2012) Novel aromatase inhibitors by structure-guided design. J Med Chem 55:8464–8476.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Gomez A,
    2. Nekvindova J,
    3. Travica S,
    4. Lee MY,
    5. Johansson I,
    6. Edler D,
    7. Mkrtchian S, and
    8. Ingelman-Sundberg M
    (2010) Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity. Mol Pharmacol 78:1004–1011.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Gonzàlez-Porta M,
    2. Frankish A,
    3. Rung J,
    4. Harrow J, and
    5. Brazma A
    (2013) Transcriptome analysis of human tissues and cell lines reveals one dominant transcript per gene. Genome Biol 14:R70.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Guantes R,
    2. Rastrojo A,
    3. Neves R,
    4. Lima A,
    5. Aguado B, and
    6. Iborra FJ
    (2015) Global variability in gene expression and alternative splicing is modulated by mitochondrial content. Genome Res 25:633–644.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Guengerich FP
    (2013) New trends in cytochrome p450 research at the half-century mark. J Biol Chem 288:17063–17064.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Hadfield KD and
    2. Newman WG
    (2012) Pharmacogenetics of aromatase inhibitors. Pharmacogenomics 13:699–707.
    OpenUrlPubMed
    1. Hampf M,
    2. Dao NT,
    3. Hoan NT, and
    4. Bernhardt R
    (2001) Unequal crossing-over between aldosterone synthase and 11beta-hydroxylase genes causes congenital adrenal hyperplasia. J Clin Endocrinol Metab 86:4445–4452.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Hanahan D and
    2. Weinberg RA
    (2011) Hallmarks of cancer: the next generation. Cell 144:646–674.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Hecker M and
    2. Ullrich V
    (1989) On the mechanism of prostacyclin and thromboxane A2 biosynthesis. J Biol Chem 264:141–150.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    1. Hines RN and
    2. McCarver DG
    (2002) The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 300:355–360.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Hochberg Z,
    2. Feil R,
    3. Constancia M,
    4. Fraga M,
    5. Junien C,
    6. Carel JC,
    7. Boileau P,
    8. Le Bouc Y,
    9. Deal CL,
    10. Lillycrop K, et al.
    (2011) Child health, developmental plasticity, and epigenetic programming. Endocr Rev 32:159–224.
    OpenUrlCrossRefPubMed
  63. ↵
    1. Horváth HC,
    2. Khabir Z,
    3. Nittke T,
    4. Gruber S,
    5. Speer G,
    6. Manhardt T,
    7. Bonner E, and
    8. Kallay E
    (2010) CYP24A1 splice variants—implications for the antitumorigenic actions of 1,25-(OH)2D3 in colorectal cancer. J Steroid Biochem Mol Biol 121:76–79.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Huang Z,
    2. Fasco MJ,
    3. Figge HL,
    4. Keyomarsi K, and
    5. Kaminsky LS
    (1996) Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 24:899–905.
    OpenUrlAbstract
  65. ↵
    1. Huang Z,
    2. Fasco MJ,
    3. Spivack S, and
    4. Kaminsky LS
    (1997) Comparisons of CYP2D messenger RNA splice variant profiles in human lung tumors and normal tissues. Cancer Res 57:2589–2592.
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. Hwang DY,
    2. Hung CC,
    3. Riepe FG,
    4. Auchus RJ,
    5. Kulle AE,
    6. Holterhus PM,
    7. Chao MC,
    8. Kuo MC,
    9. Hwang SJ, and
    10. Chen HC
    (2011) CYP17A1 intron mutation causing cryptic splicing in 17α-hydroxylase deficiency. PLoS One 6:e25492.
    OpenUrlPubMed
  67. ↵
    1. Ibeanu GC,
    2. Blaisdell J,
    3. Ferguson RJ,
    4. Ghanayem BI,
    5. Brosen K,
    6. Benhamou S,
    7. Bouchardy C,
    8. Wilkinson GR,
    9. Dayer P, and
    10. Goldstein JA
    (1999) A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 290:635–640.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Johnson CS,
    2. Chung I, and
    3. Trump DL
    (2010) Epigenetic silencing of CYP24 in the tumor microenvironment. J Steroid Biochem Mol Biol 121:338–342.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Johnson EF and
    2. Stout CD
    (2013) Structural diversity of eukaryotic membrane cytochrome p450s. J Biol Chem 288:17082–17090.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Kimouli M,
    2. Gourvas V,
    3. Konstantoudaki X,
    4. Basta M,
    5. Miyakis S, and
    6. Spandidos DA
    (2009) The effect of an exon 12 polymorphism of the human thromboxane synthase (CYP5A1) gene in stroke patients. Med Sci Monit 15:BR30–BR35.
    OpenUrlPubMed
  71. ↵
    1. Knüpfer H,
    2. Schmidt R,
    3. Stanitz D,
    4. Brauckhoff M,
    5. Schönfelder M, and
    6. Preiss R
    (2004) CYP2C and IL-6 expression in breast cancer. Breast 13:28–34.
    OpenUrlCrossRefPubMed
  72. ↵
    1. Kommaddi RP,
    2. Turman CM,
    3. Moorthy B,
    4. Wang L,
    5. Strobel HW, and
    6. Ravindranath V
    (2007) An alternatively spliced cytochrome P4501A1 in human brain fails to bioactivate polycyclic aromatic hydrocarbons to DNA-reactive metabolites. J Neurochem 102:867–877.
    OpenUrlPubMed
  73. ↵
    1. Kramlinger VM,
    2. Nagy LD,
    3. Fujiwara R,
    4. Johnson KM,
    5. Phan TT,
    6. Xiao Y,
    7. Enright JM,
    8. Toomey MB,
    9. Corbo JC, and
    10. Guengerich FP
    (2016) Human cytochrome P450 27C1 catalyzes 3,4-desaturation of retinoids. FEBS Lett 590:1304–1312.
    OpenUrl
  74. ↵
    1. Kristensen VN,
    2. Harada N,
    3. Yoshimura N,
    4. Haraldsen E,
    5. Lonning PE,
    6. Erikstein B,
    7. Kåresen R,
    8. Kristensen T, and
    9. Børresen-Dale AL
    (2000) Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 19:1329–1333.
    OpenUrlCrossRefPubMed
  75. ↵
    1. Kuehl P,
    2. Zhang J,
    3. Lin Y,
    4. Lamba J,
    5. Assem M,
    6. Schuetz J,
    7. Watkins PB,
    8. Daly A,
    9. Wrighton SA,
    10. Hall SD, et al.
    (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391.
    OpenUrlCrossRefPubMed
  76. ↵
    1. La Cognata V,
    2. Iemmolo R,
    3. D’Agata V,
    4. Scuderi S,
    5. Drago F,
    6. Zappia M, and
    7. Cavallaro S
    (2014) Increasing the coding potential of genomes through alternative splicing: The case of PARK2 gene. Curr Genomics 15:203–216.
    OpenUrl
  77. ↵
    1. Lamb DC and
    2. Waterman MR
    (2013) Unusual properties of the cytochrome P450 superfamily. Philos Trans R Soc Lond B Biol Sci 368:20120434.
    OpenUrlAbstract/FREE Full Text
  78. ↵
    1. Lander ES,
    2. Linton LM,
    3. Birren B,
    4. Nusbaum C,
    5. Zody MC,
    6. Baldwin J,
    7. Devon K,
    8. Dewar K,
    9. Doyle M,
    10. FitzHugh W, et al., and International Human Genome Sequencing Consortium
    (2001) Initial sequencing and analysis of the human genome. Nature 409:860–921.
    OpenUrlCrossRefPubMed
  79. ↵
    1. Larriba MJ,
    2. González-Sancho JM,
    3. Bonilla F, and
    4. Muñoz A
    (2014) Interaction of vitamin D with membrane-based signaling pathways. Front Physiol 5:60.
    OpenUrlPubMed
  80. ↵
    1. Lee HH
    (2013) Variants of the CYP21A2 and CYP21A1P genes in congenital adrenal hyperplasia. Clin Chim Acta 418:37–44.
    OpenUrl
  81. ↵
    1. Lee SJ,
    2. van der Heiden IP,
    3. Goldstein JA, and
    4. van Schaik RH
    (2007) A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system. Drug Metab Dispos 35:67–71.
    OpenUrlAbstract/FREE Full Text
  82. ↵
    1. Lejeune F and
    2. Maquat LE
    (2005) Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. Curr Opin Cell Biol 17:309–315.
    OpenUrlCrossRefPubMed
  83. ↵
    1. Leung YK,
    2. Lau KM,
    3. Mobley J,
    4. Jiang Z, and
    5. Ho SM
    (2005) Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res 65:3726–3734.
    OpenUrlAbstract/FREE Full Text
  84. ↵
    1. Lewiñska M,
    2. Zmrzljak UP, and
    3. Rozman D
    (2013) Low nucleotide variability of CYP51A1 in humans: meta-analysis of cholesterol and bile acid synthesis and xenobiotic metabolism pathways. Acta Chim Slov 60:875–883.
    OpenUrl
    1. Li F,
    2. Jiang C,
    3. Larsen MC,
    4. Bushkofsky J,
    5. Krausz KW,
    6. Wang T,
    7. Jefcoate CR, and
    8. Gonzalez FJ
    (2014) Lipidomics reveals a link between CYP1B1 and SCD1 in promoting obesity. J Proteome Res 13:2679–2687.
    OpenUrlCrossRefPubMed
    1. Li M,
    2. Wang W,
    3. Li Y,
    4. Wang L,
    5. Shen X, and
    6. Tang Z
    (2013a) CYP46A1 intron-2T/C polymorphism and Alzheimer’s disease: an updated meta-analysis of 16 studies including 3,960 cases and 3,828 controls. Neurosci Lett 549:18–23.
    OpenUrl
    1. Li L,
    2. Yin Z,
    3. Liu J,
    4. Li G,
    5. Wang Y,
    6. Yan J, and
    7. Zhou H
    (2013b) CYP46A1 T/C polymorphism associated with the APOE ε4 allele increases the risk of Alzheimer’s disease. J Neurol 260:1701–1708.
    OpenUrlCrossRefPubMed
  85. ↵
    1. Lin L,
    2. Ercan O,
    3. Raza J,
    4. Burren CP,
    5. Creighton SM,
    6. Auchus RJ,
    7. Dattani MT, and
    8. Achermann JC
    (2007) Variable phenotypes associated with aromatase (CYP19) insufficiency in humans. J Clin Endocrinol Metab 92:982–990.
    OpenUrlCrossRefPubMed
  86. ↵
    1. Lin YS,
    2. Dowling ALS,
    3. Quigley SD,
    4. Farin FM,
    5. Zhang J,
    6. Lamba J,
    7. Schuetz EG, and
    8. Thummel KE
    (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162–172.
    OpenUrlAbstract/FREE Full Text
  87. ↵
    1. Liu L,
    2. Bai YX,
    3. Zhou JH,
    4. Sun XW,
    5. Sui H,
    6. Zhang WJ,
    7. Yuan HH,
    8. Xie R,
    9. Wei XL,
    10. Zhang TT, et al.
    (2013a) A polymorphism at the 3′-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma. Int J Mol Sci 14:18973–18988.
    OpenUrl
  88. ↵
    1. Liu X,
    2. Low SK, and
    3. Boddy AV
    (2016) The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors. Expert Opin Drug Metab Toxicol 12:851–863.
    OpenUrl
    1. Liu YL,
    2. Xu Y,
    3. Li F,
    4. Chen H, and
    5. Guo SL
    (2013b) CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis. Tumour Biol 34:2651–2657.
    OpenUrlCrossRefPubMed
  89. ↵
    1. Lu Y,
    2. Mo C,
    3. Zeng Z,
    4. Chen S,
    5. Xie Y,
    6. Peng Q,
    7. He Y,
    8. Deng Y,
    9. Wang J,
    10. Xie L, et al.
    (2013) CYP2D6*4 allele polymorphism increases the risk of Parkinson’s disease: evidence from meta-analysis. PLoS One 8:e84413.
    OpenUrl
  90. ↵
    1. Lum DW,
    2. Perel P,
    3. Hingorani AD, and
    4. Holmes MV
    (2013) CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS One 8:e76648.
    OpenUrlCrossRefPubMed
  91. ↵
    1. Maas RM,
    2. Reus K,
    3. Diesel B,
    4. Steudel WI,
    5. Feiden W,
    6. Fischer U, and
    7. Meese E
    (2001) Amplification and expression of splice variants of the gene encoding the P450 cytochrome 25-hydroxyvitamin D(3) 1,alpha-hydroxylase (CYP 27B1) in human malignant glioma. Clin Cancer Res 7:868–875.
    OpenUrlAbstract/FREE Full Text
  92. ↵
    1. Mahadevan B,
    2. Arora V,
    3. Schild LJ,
    4. Keshava C,
    5. Cate ML,
    6. Iversen PL,
    7. Poirier MC,
    8. Weston A,
    9. Pereira C, and
    10. Baird WM
    (2006) Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology. Mol Carcinog 45:118–125.
    OpenUrlCrossRefPubMed
  93. ↵
    1. Mangin M,
    2. Sinha R, and
    3. Fincher K
    (2014) Inflammation and vitamin D: the infection connection. Inflamm Res 63:803–819.
    OpenUrlCrossRefPubMed
  94. ↵
    1. Matsuda S and
    2. Kitagishi Y
    (2013) Peroxisome proliferator-activated receptor and vitamin d receptor signaling pathways in cancer cells. Cancers (Basel) 5:1261–1270.
    OpenUrl
  95. ↵
    1. McClorey G,
    2. Fall AM,
    3. Moulton HM,
    4. Iversen PL,
    5. Rasko JE,
    6. Ryan M,
    7. Fletcher S, and
    8. Wilton SD
    (2006a) Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord 16:583–590.
    OpenUrlCrossRefPubMed
  96. ↵
    1. McClorey G,
    2. Moulton HM,
    3. Iversen PL,
    4. Fletcher S, and
    5. Wilton SD
    (2006b) Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13:1373–1381.
    OpenUrlCrossRefPubMed
  97. ↵
    1. McGlincy NJ and
    2. Smith CW
    (2008) Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense? Trends Biochem Sci 33:385–393.
    OpenUrlCrossRefPubMed
  98. ↵
    1. Meyer UA
    (2007) Endo-xenobiotic crosstalk and the regulation of cytochromes P450. Drug Metab Rev 39:639–646.
    OpenUrlCrossRefPubMed
  99. ↵
    1. Miles JS,
    2. McLaren AW, and
    3. Wolf CR
    (1989) Alternative splicing in the human cytochrome P450IIB6 gene generates a high level of aberrant messages. Nucleic Acids Res 17:8241–8255.
    OpenUrlAbstract/FREE Full Text
  100. ↵
    1. Mitrpant C,
    2. Fletcher S,
    3. Iversen PL, and
    4. Wilton SD
    (2009) By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping. J Gene Med 11:46–56.
    OpenUrlPubMed
  101. ↵
    1. Monsalve M,
    2. Wu Z,
    3. Adelmant G,
    4. Puigserver P,
    5. Fan M, and
    6. Spiegelman BM
    (2000) Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. Mol Cell 6:307–316.
    OpenUrlCrossRefPubMed
  102. ↵
    1. Mort M,
    2. Ivanov D,
    3. Cooper DN, and
    4. Chuzhanova NA
    (2008) A meta-analysis of nonsense mutations causing human genetic disease. Hum Mutat 29:1037–1047.
    OpenUrlCrossRefPubMed
  103. ↵
    1. Mourich DV and
    2. Iversen PL
    (2009) Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing. Curr Opin Mol Ther 11:124–132.
    OpenUrlPubMed
  104. ↵
    1. Mourich DV,
    2. Oda SK,
    3. Schnell FJ,
    4. Crumley SL,
    5. Hauck LL,
    6. Moentenich CA,
    7. Marshall NB,
    8. Hinrichs DJ, and
    9. Iversen PL
    (2014) Alternative splice forms of CTLA-4 induced by antisense mediated splice-switching influences autoimmune diabetes susceptibility in NOD mice. Nucleic Acid Ther 24:114–126.
    OpenUrlCrossRefPubMed
  105. ↵
    1. Muindi JR,
    2. Nganga A,
    3. Engler KL,
    4. Coignet LJ,
    5. Johnson CS, and
    6. Trump DL
    (2007) CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. J Steroid Biochem Mol Biol 103:334–337.
    OpenUrlCrossRefPubMed
    1. Nakayama T,
    2. Soma M,
    3. Saito S,
    4. Honye J,
    5. Yajima J,
    6. Rahmutula D,
    7. Kaneko Y,
    8. Sato M,
    9. Uwabo J,
    10. Aoi N, et al.
    (2002a) Association of a novel single nucleotide polymorphism of the prostacyclin synthase gene with myocardial infarction. Am Heart J 143:797–801.
    OpenUrlCrossRefPubMed
    1. Nakayama T,
    2. Soma M,
    3. Watanabe Y,
    4. Hasimu B,
    5. Sato M,
    6. Aoi N,
    7. Kosuge K,
    8. Kanmatsuse K,
    9. Kokubun S,
    10. Marrow JD, et al.
    (2002b) Splicing mutation of the prostacyclin synthase gene in a family associated with hypertension. Biochem Biophys Res Commun 297:1135–1139.
    OpenUrlCrossRefPubMed
  106. ↵
    1. Nelson DR
    (2003) Comparison of P450s from human and fugu: 420 million years of vertebrate P450 evolution. Arch Biochem Biophys 409:18–24.
    OpenUrlCrossRefPubMed
  107. ↵
    1. Nelson DR,
    2. Zeldin DC,
    3. Hoffman SM,
    4. Maltais LJ,
    5. Wain HM, and
    6. Nebert DW
    (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1–18.
    OpenUrlCrossRefPubMed
  108. ↵
    1. Nhamburo PT,
    2. Kimura S,
    3. McBride OW,
    4. Kozak CA,
    5. Gelboin HV, and
    6. Gonzalez FJ
    (1990) The human CYP2F gene subfamily: identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping. Biochemistry 29:5491–5499.
    OpenUrlCrossRefPubMed
  109. ↵
    1. Niks EH and
    2. Aartsma-Rus A
    (2017) Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin Biol Ther 17:225–236.
    OpenUrl
  110. ↵
    1. Ohgiya S,
    2. Komori M,
    3. Ohi H,
    4. Shiramatsu K,
    5. Shinriki N, and
    6. Kamataki T
    (1992) Six-base deletion occurring in messages of human cytochrome P-450 in the CYP2C subfamily results in reduction of tolbutamide hydroxylase activity. Biochem Int 27:1073–1081.
    OpenUrlPubMed
  111. ↵
    1. Okino ST,
    2. Quattrochi LC,
    3. Pendurthi UR,
    4. McBride OW, and
    5. Tukey RH
    (1987) Characterization of multiple human cytochrome P-450 1 cDNAs. The chromosomal localization of the gene and evidence for alternate RNA splicing. J Biol Chem 262:16072–16079.
    OpenUrlAbstract/FREE Full Text
  112. ↵
    1. Pagliarini V,
    2. Naro C, and
    3. Sette C
    (2015) Splicing Regulation: A Molecular Device to Enhance Cancer Cell Adaptation. BioMed Res Int 2015:543067.
    OpenUrl
  113. ↵
    1. Panchal RG,
    2. Ulrich RL,
    3. Bradfute SB,
    4. Lane D,
    5. Ruthel G,
    6. Kenny TA,
    7. Iversen PL,
    8. Anderson AO,
    9. Gussio R,
    10. Raschke WC, et al.
    (2009) Reduced expression of CD45 protein-tyrosine phosphatase provides protection against anthrax pathogenesis. J Biol Chem 284:12874–12885.
    OpenUrlAbstract/FREE Full Text
  114. ↵
    1. Panchal RG,
    2. Mourich DV,
    3. Bradfute S,
    4. Hauck LL,
    5. Warfield KL,
    6. Iversen PL, and
    7. Bavari S
    (2014) Induced IL-10 splice altering approach to antiviral drug discovery. Nucleic Acid Ther 24:179–185.
    OpenUrlCrossRefPubMed
  115. ↵
    1. Park JW,
    2. Reed JR, and
    3. Backes WL
    (2015) The localization of cytochrome P450s CYP1A1 and CYP1A2 into different lipid microdomains is governed by their N-terminal and internal protein regions. J Biol Chem 290:29449–29460.
    OpenUrlAbstract/FREE Full Text
  116. ↵
    1. Peng X,
    2. Tiwari N,
    3. Roy S,
    4. Yuan L,
    5. Murillo G,
    6. Mehta RR,
    7. Benya RV, and
    8. Mehta RG
    (2012) Regulation of CYP24 splicing by 1,25-dihydroxyvitamin D3 in human colon cancer cells. J Endocrinol 212:207–215.
    OpenUrlAbstract/FREE Full Text
  117. ↵
    1. Pepe CM,
    2. Saraco NI,
    3. Baquedano MS,
    4. Guercio G,
    5. Vaiani E,
    6. Marino R,
    7. Pandey AV,
    8. Flück CE,
    9. Rivarola MA, and
    10. Belgorosky A
    (2007) The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of nonclassic aromatase deficiency and is also present in normal human steroidogenic tissues. Clin Endocrinol (Oxf) 67:698–705.
    OpenUrlCrossRefPubMed
  118. ↵
    1. Pikuleva IA and
    2. Waterman MR
    (2013) Cytochromes p450: roles in diseases. J Biol Chem 288:17091–17098.
    OpenUrlAbstract/FREE Full Text
  119. ↵
    1. Qiao J,
    2. Han B,
    3. Liu BL,
    4. Liu W,
    5. Wu JJ,
    6. Pan CM,
    7. Jiang H,
    8. Gu T,
    9. Jiang BR,
    10. Zhu H, et al.
    (2011) A unique exonic splicing mutation in the CYP17A1 gene as the cause for steroid 17alpha-hydroxylase deficiency. Eur J Endocrinol 164:627–633.
    OpenUrlAbstract/FREE Full Text
  120. ↵
    1. Qu G,
    2. Dong X,
    3. Piazza CL,
    4. Chalamcharla VR,
    5. Lutz S,
    6. Curcio MJ, and
    7. Belfort M
    (2014) RNA-RNA interactions and pre-mRNA mislocalization as drivers of group II intron loss from nuclear genomes. Proc Natl Acad Sci USA 111:6612–6617.
    OpenUrlAbstract/FREE Full Text
  121. ↵
    1. Raj A and
    2. van Oudenaarden A
    (2008) Nature, nurture, or chance: stochastic gene expression and its consequences. Cell 135:216–226.
    OpenUrlCrossRefPubMed
  122. ↵
    Rappaport N, Twik M, Nativ N, Stelzer G, Bahir I, Stein TI, Safran M, Lancet D. (2014) MalaCards: a comprehensive automatically mined database of human diseases. Curr Protoc Bioinformatics 47:1.24.1–1.24.19 DOI: 10.1002/0471250953.bi0124s47 (published online).
  123. ↵
    1. Rat E,
    2. Billaut-Laden I,
    3. Allorge D,
    4. Lo-Guidice JM,
    5. Tellier M,
    6. Cauffiez C,
    7. Jonckheere N,
    8. van Seuningen I,
    9. Lhermitte M,
    10. Romano A, et al.
    (2006) Evidence for a functional genetic polymorphism of the human retinoic acid-metabolizing enzyme CYP26A1, an enzyme that may be involved in spina bifida. Birth Defects Res A Clin Mol Teratol 76:491–498.
    OpenUrlPubMed
  124. ↵
    1. Ren S,
    2. Nguyen L,
    3. Wu S,
    4. Encinas C,
    5. Adams JS, and
    6. Hewison M
    (2005) Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J Biol Chem 280:20604–20611.
    OpenUrlAbstract/FREE Full Text
  125. ↵
    1. Rhieu SY,
    2. Annalora AJ,
    3. Wang G,
    4. Flarakos CC,
    5. Gathungu RM,
    6. Vouros P,
    7. Sigüeiro R,
    8. Mouriño A,
    9. Schuster I,
    10. Palmore GT, et al.
    (2013) Metabolic stability of 3-epi-1α,25-dihydroxyvitamin D3 over 1 α 25-dihydroxyvitamin D3: metabolism and molecular docking studies using rat CYP24A1. J Cell Biochem 114:2293–2305.
    OpenUrl
  126. ↵
    1. Robins T,
    2. Carlsson J,
    3. Sunnerhagen M,
    4. Wedell A, and
    5. Persson B
    (2006) Molecular model of human CYP21 based on mammalian CYP2C5: structural features correlate with clinical severity of mutations causing congenital adrenal hyperplasia. Mol Endocrinol 20:2946–2964.
    OpenUrlCrossRefPubMed
  127. ↵
    1. Rogozin IB,
    2. Carmel L,
    3. Csuros M, and
    4. Koonin EV
    (2012) Origin and evolution of spliceosomal introns. Biol Direct 7:11.
    OpenUrlCrossRefPubMed
  128. ↵
    1. Roy B,
    2. Haupt LM, and
    3. Griffiths LR
    (2013) Review: Alternate splicing (AS) of genes as an approach for generating protein complexity. Curr Genomics 14:182–194.
    OpenUrlCrossRefPubMed
  129. ↵
    1. Salzman J,
    2. Gawad C,
    3. Wang PL,
    4. Lacayo N, and
    5. Brown PO
    (2012) Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One 7:e30733.
    OpenUrlCrossRefPubMed
  130. ↵
    1. Sangar MC,
    2. Anandatheerthavarada HK,
    3. Martin MV,
    4. Guengerich FP, and
    5. Avadhani NG
    (2010) Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting. Mol Genet Metab 99:90–97.
    OpenUrlCrossRefPubMed
  131. ↵
    1. Sarasquete ME,
    2. García-Sanz R,
    3. Marín L,
    4. Alcoceba M,
    5. Chillón MC,
    6. Balanzategui A,
    7. Santamaria C,
    8. Rosiñol L,
    9. de la Rubia J,
    10. Hernandez MT, et al.
    (2008) Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112:2709–2712.
    OpenUrlAbstract/FREE Full Text
  132. ↵
    1. Satyanarayana CR,
    2. Devendran A,
    3. Jayaraman M,
    4. Mannu J,
    5. Mathur PP,
    6. Gopal SD,
    7. Rajagopal K, and
    8. Chandrasekaran A
    (2009) Influence of the genetic polymorphisms in the 5′ flanking and exonic regions of CYP2C19 on proguanil oxidation. Drug Metab Pharmacokinet 24:537–548.
    OpenUrlPubMed
  133. ↵
    1. Scheible C,
    2. Thill M,
    3. Baum S,
    4. Solomayer E, and
    5. Friedrich M
    (2014) Implication of CYP24A1 splicing in breast cancer. Anticancer Agents Med Chem 14:109–114.
    OpenUrl
  134. ↵
    1. Searles Nielsen S,
    2. Bammler TK,
    3. Gallagher LG,
    4. Farin FM,
    5. Longstreth Jr W,
    6. Franklin GM,
    7. Swanson PD, and
    8. Checkoway H
    (2013) Genotype and age at Parkinson disease diagnosis. Int J Mol Epidemiol Genet 4:61–69.
    OpenUrl
  135. ↵
    1. Seifert M,
    2. Tilgen W, and
    3. Reichrath J
    (2009) Expression of 25-hydroxyvitamin D-1alpha-hydroxylase (1alphaOHase, CYP27B1) splice variants in HaCaT keratinocytes and other skin cells: modulation by culture conditions and UV-B treatment in vitro. Anticancer Res 29:3659–3667.
    OpenUrlAbstract/FREE Full Text
  136. ↵
    1. Sevrioukova IF and
    2. Poulos TL
    (2013) Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues. Biochemistry 52:4474–4481.
    OpenUrlCrossRefPubMed
  137. ↵
    1. Sharaf S,
    2. Hafez M,
    3. ElAbd D,
    4. Ismail A,
    5. Thabet G, and
    6. Elsharkawy M
    (2015) High frequency of splice site mutation in 21-hydroxylase deficiency children. J Endocrinol Invest 38:505–511.
    OpenUrl
  138. ↵
    1. Sheikh SA,
    2. Waryah AM,
    3. Narsani AK,
    4. Shaikh H,
    5. Gilal IA,
    6. Shah K,
    7. Qasim M,
    8. Memon AI,
    9. Kewalramani P, and
    10. Shaikh N
    (2014) Mutational spectrum of the CYP1B1 gene in Pakistani patients with primary congenital glaucoma: novel variants and genotype-phenotype correlations. Mol Vis 20:991–1001.
    OpenUrl
  139. ↵
    1. Shuldiner AR,
    2. O’Connell JR,
    3. Bliden KP,
    4. Gandhi A,
    5. Ryan K,
    6. Horenstein RB,
    7. Damcott CM,
    8. Pakyz R,
    9. Tantry US,
    10. Gibson Q, et al.
    (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849–857.
    OpenUrlCrossRefPubMed
  140. ↵
    1. Slavotinek AM,
    2. Mehrotra P,
    3. Nazarenko I,
    4. Tang PL,
    5. Lao R,
    6. Cameron D,
    7. Li B,
    8. Chu C,
    9. Chou C,
    10. Marqueling AL, et al.
    (2013) Focal facial dermal dysplasia, type IV, is caused by mutations in CYP26C1. Hum Mol Genet 22:696–703.
    OpenUrlAbstract/FREE Full Text
  141. ↵
    1. Solomon O,
    2. Oren S,
    3. Safran M,
    4. Deshet-Unger N,
    5. Akiva P,
    6. Jacob-Hirsch J,
    7. Cesarkas K,
    8. Kabesa R,
    9. Amariglio N,
    10. Unger R, et al.
    (2013) Global regulation of alternative splicing by adenosine deaminase acting on RNA (ADAR). RNA 19:591–604.
    OpenUrlAbstract/FREE Full Text
  142. ↵
    1. Stelzer G,
    2. Dalah I,
    3. Stein TI,
    4. Satanower Y,
    5. Rosen N,
    6. Nativ N,
    7. Oz-Levi D,
    8. Olender T,
    9. Belinky F,
    10. Bahir I, et al.
    (2011) In-silico human genomics with GeneCards. Hum Genomics 5:709–717.
    OpenUrlCrossRefPubMed
  143. ↵
    1. Stenstedt K,
    2. Hallstrom M,
    3. Johansson I,
    4. Ingelman-Sundberg M,
    5. Ragnhammar P, and
    6. Edler D
    (2012) The expression of CYP2W1: a prognostic marker in colon cancer. Anticancer Res 32:3869–3874.
    OpenUrlAbstract/FREE Full Text
  144. ↵
    1. St. Laurent G,
    2. Vyatkin Y, and
    3. Kapranov P
    (2014) Dark matter RNA illuminates the puzzle of genome-wide association studies. BMC Med 12:97–105.
    OpenUrlCrossRefPubMed
  145. ↵
    1. Stoilov I,
    2. Akarsu AN,
    3. Alozie I,
    4. Child A,
    5. Barsoum-Homsy M,
    6. Turacli ME,
    7. Or M,
    8. Lewis RA,
    9. Ozdemir N,
    10. Brice G, et al.
    (1998) Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 62:573–584.
    OpenUrlCrossRefPubMed
  146. ↵
    1. Sun W,
    2. Li Y,
    3. Li J,
    4. Zhang Z,
    5. Zhu W,
    6. Liu W,
    7. Cai Q,
    8. Wang X,
    9. Cao L,
    10. Bai W, et al.
    (2015) Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Platelets 26:558–562.
    OpenUrl
  147. ↵
    1. Syed YY
    (2016) Eteplirsen: First Global Approval. Drugs 76:1699–1704.
    OpenUrl
  148. ↵
    1. Szabó JA,
    2. Szilágyi Á,
    3. Doleschall Z,
    4. Patócs A,
    5. Farkas H,
    6. Prohászka Z,
    7. Rácz K,
    8. Füst G, and
    9. Doleschall M
    (2013) Both positive and negative selection pressures contribute to the polymorphism pattern of the duplicated human CYP21A2 gene. PLoS One 8:e81977.
    OpenUrl
  149. ↵
    1. Tanwar M,
    2. Dada T,
    3. Sihota R,
    4. Das TK,
    5. Yadav U, and
    6. Dada R
    (2009) Mutation spectrum of CYP1B1 in North Indian congenital glaucoma patients. Mol Vis 15:1200–1209.
    OpenUrlPubMed
  150. ↵
    1. Thierry-Mieg D and
    2. Thierry-Mieg J
    . (2006) AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol 1:S12.1-14.
  151. ↵
    1. Tian D and
    2. Zhang ZQ
    (2011) 2 Novel deletions of the sterol 27-hydroxylase gene in a Chinese Family with Cerebrotendinous Xanthomatosis. BMC Neurol 11:130.
    OpenUrlPubMed
  152. ↵
    1. Toscano C,
    2. Klein K,
    3. Blievernicht J,
    4. Schaeffeler E,
    5. Saussele T,
    6. Raimundo S,
    7. Eichelbaum M,
    8. Schwab M, and
    9. Zanger UM
    (2006) Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics 16:755–766.
    OpenUrlCrossRefPubMed
  153. ↵
    1. Tournel G,
    2. Cauffiez C,
    3. Billaut-Laden I,
    4. Allorge D,
    5. Chevalier D,
    6. Bonnifet F,
    7. Mensier E,
    8. Lafitte JJ,
    9. Lhermitte M,
    10. Broly F, et al.
    (2007) Molecular analysis of the CYP2F1 gene: identification of a frequent non-functional allelic variant. Mutat Res 617:79–89.
    OpenUrlPubMed
  154. ↵
    1. Tralau T and
    2. Luch A
    (2013) The evolution of our understanding of endo-xenobiotic crosstalk and cytochrome P450 regulation and the therapeutic implications. Expert Opin Drug Metab Toxicol 9:1541–1554.
    OpenUrlCrossRefPubMed
  155. ↵
    1. Trump DL,
    2. Muindi J,
    3. Fakih M,
    4. Yu WD, and
    5. Johnson CS
    (2006) Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res 26 (4A):2551–2556.
    OpenUrlAbstract/FREE Full Text
  156. ↵
    1. Turman CM,
    2. Hatley JM,
    3. Ryder DJ,
    4. Ravindranath V, and
    5. Strobel HW
    (2006) Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: The convolution continues. Expert Opin Drug Metab Toxicol 2:399–418.
    OpenUrlCrossRefPubMed
  157. ↵
    1. Vanselow J,
    2. Zsolnai A,
    3. Fésüs L,
    4. Fürbass R, and
    5. Schwerin M
    (1999) Placenta-specific transcripts of the aromatase encoding gene include different untranslated first exons in sheep and cattle. Eur J Biochem 265:318–324.
    OpenUrlPubMed
  158. ↵
    1. Verrips A,
    2. Steenbergen-Spanjers GC,
    3. Luyten JA,
    4. Wevers RA,
    5. Wokke JH,
    6. Gabreëls FJ,
    7. Wolthers BG, and
    8. van den Heuvel LP
    (1997) Exon skipping in the sterol 27-hydroxylase gene leads to cerebrotendinous xanthomatosis. Hum Genet 100:284–286.
    OpenUrlCrossRefPubMed
  159. ↵
    1. Walsh AA,
    2. Szklarz GD, and
    3. Scott EE
    (2013) Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J Biol Chem 288:12932–12943.
    OpenUrlAbstract/FREE Full Text
  160. ↵
    1. Wang A,
    2. Stout CD,
    3. Zhang Q, and
    4. Johnson EF
    (2015) Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding. J Biol Chem 290:5092–5104.
    OpenUrlAbstract/FREE Full Text
  161. ↵
    1. Wang D,
    2. Poi MJ,
    3. Sun X,
    4. Gaedigk A,
    5. Leeder JS, and
    6. Sadee W
    (2014) Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet 23:268–278.
    OpenUrlAbstract/FREE Full Text
  162. ↵
    1. Wang LH,
    2. Tazawa R,
    3. Lang AQ, and
    4. Wu KK
    (1994) Alternate splicing of human thromboxane synthase mRNA. Arch Biochem Biophys 315:273–278.
    OpenUrlCrossRefPubMed
  163. ↵
    1. Wang W,
    2. Fu JF,
    3. Gong FQ,
    4. Zhu WH, and
    5. Shen Z
    (2011) Rare hypertension as a result of 17alpha-hydroxylase deficiency. J Pediatr Endocrinol Metab 24:333–337.
    OpenUrlPubMed
  164. ↵
    1. Wang Z and
    2. Burge CB
    (2008) Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA 14:802–813.
    OpenUrlAbstract/FREE Full Text
  165. ↵
    1. Warner SC,
    2. Finta C, and
    3. Zaphiropoulos PG
    (2001) Intergenic transcripts containing a novel human cytochrome P450 2C exon 1 spliced to sequences from the CYP2C9 gene. Mol Biol Evol 18:1841–1848.
    OpenUrlAbstract/FREE Full Text
  166. ↵
    1. Wiemann S,
    2. Kolb-Kokocinski A, and
    3. Poustka A
    (2005) Alternative pre-mRNA processing regulates cell-type specific expression of the IL4l1 and NUP62 genes. BMC Biol 3:16.
    OpenUrlCrossRefPubMed
  167. ↵
    1. Wu AH
    (2011) Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin Proteomics 8:12–21.
    OpenUrlCrossRefPubMed
  168. ↵
    1. Wu S,
    2. Ren S,
    3. Nguyen L,
    4. Adams JS, and
    5. Hewison M
    (2007) Splice variants of the CYP27b1 gene and the regulation of 1,25-dihydroxyvitamin D3 production. Endocrinology 148:3410–3418.
    OpenUrlCrossRefPubMed
  169. ↵
    1. Wu Z,
    2. Puigserver P,
    3. Andersson U,
    4. Zhang C,
    5. Adelmant G,
    6. Mootha V,
    7. Troy A,
    8. Cinti S,
    9. Lowell B,
    10. Scarpulla RC, et al.
    (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:115–124.
    OpenUrlCrossRefPubMed
  170. ↵
    1. Wu ZL,
    2. Bartleson CJ,
    3. Ham AJ, and
    4. Guengerich FP
    (2006) Heterologous expression, purification, and properties of human cytochrome P450 27C1. Arch Biochem Biophys 445:138–146.
    OpenUrlCrossRefPubMed
  171. ↵
    1. Yamaguchi H,
    2. Nakazato M,
    3. Miyazato M,
    4. Toshimori H,
    5. Oki S,
    6. Shimizu K,
    7. Suiko M,
    8. Kangawa K, and
    9. Matsukura S
    (1998) Identification of a novel splicing mutation and 1-bp deletion in the 17alpha-hydroxylase gene of Japanese patients with 17alpha-hydroxylase deficiency. Hum Genet 102:635–639.
    OpenUrlCrossRefPubMed
  172. ↵
    1. Yamano S,
    2. Nhamburo PT,
    3. Aoyama T,
    4. Meyer UA,
    5. Inaba T,
    6. Kalow W,
    7. Gelboin HV,
    8. McBride OW, and
    9. Gonzalez FJ
    (1989) cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 28:7340–7348.
    OpenUrlCrossRefPubMed
  173. ↵
    1. Zanger UM and
    2. Schwab M
    (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141.
    OpenUrlCrossRefPubMed
  174. ↵
    1. Zaphiropoulos PG
    (1997) Exon skipping and circular RNA formation in transcripts of the human cytochrome P-450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Mol Cell Biol 17:2985–2993.
    OpenUrlAbstract/FREE Full Text
  175. ↵
    1. Zaphiropoulos PG
    (1999) RNA molecules containing exons originating from different members of the cytochrome P450 2C gene subfamily (CYP2C) in human epidermis and liver. Nucleic Acids Res 27:2585–2590.
    OpenUrlAbstract/FREE Full Text
  176. ↵
    1. Zhang C,
    2. Dowd DR,
    3. Staal A,
    4. Gu C,
    5. Lian JB,
    6. van Wijnen AJ,
    7. Stein GS, and
    8. MacDonald PN
    (2003) Nuclear coactivator-62 kDa/Ski-interacting protein is a nuclear matrix-associated coactivator that may couple vitamin D receptor-mediated transcription and RNA splicing. J Biol Chem 278:35325–35336.
    OpenUrlAbstract/FREE Full Text
  177. ↵
    1. Zhang C,
    2. Wang L,
    3. Liao Q,
    4. Zhang L,
    5. Xu L,
    6. Chen C,
    7. Ye H,
    8. Xu X,
    9. Ye M, and
    10. Duan S
    (2013) Genetic associations with hypertension: meta-analyses of six candidate genetic variants. Genet Test Mol Biomarkers 17:736–742.
    OpenUrlCrossRefPubMed
  178. ↵
    1. Zhao Y,
    2. Goto K,
    3. Saitoh M,
    4. Yanase T,
    5. Nomura M,
    6. Okabe T,
    7. Takayanagi R, and
    8. Nawata H
    (2002) Activation function-1 domain of androgen receptor contributes to the interaction between subnuclear splicing factor compartment and nuclear receptor compartment. Identification of the p102 U5 small nuclear ribonucleoprotein particle-binding protein as a coactivator for the receptor. J Biol Chem 277:30031–30039.
    OpenUrlAbstract/FREE Full Text
  179. ↵
    1. Zhao B and
    2. Waterman MR
    (2011) Moonlighting cytochrome P450 monooxygenases. IUBMB Life 63:473–477.
    OpenUrlCrossRefPubMed
  180. ↵
    1. Zhou C,
    2. Zhou D,
    3. Esteban J,
    4. Murai J,
    5. Siiteri PK,
    6. Wilczynski S, and
    7. Chen S
    (1996) Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 59:163–171.
    OpenUrlCrossRefPubMed
  181. ↵
    1. Zhou R,
    2. Chun RF,
    3. Lisse TS,
    4. Garcia AJ,
    5. Xu J,
    6. Adams JS, and
    7. Hewison M
    (2015) Vitamin D and alternative splicing of RNA. J Steroid Biochem Mol Biol (148):310–317.
    OpenUrl
  182. ↵
    1. Zhou SF,
    2. Liu JP, and
    3. Chowbay B
    (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295.
    OpenUrlCrossRefPubMed
  183. ↵
    1. Zhou SF
    (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48:689–723.
    OpenUrl
  184. ↵
    1. Zimmerly S and
    2. Semper C
    (2015) Evolution of group II introns. Mob DNA 6:7.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 45 (4)
Drug Metabolism and Disposition
Vol. 45, Issue 4
1 Apr 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Alternative Splicing in the Cytochrome P450 Superfamily Expands Protein Diversity to Augment Gene Function and Redirect Human Drug Metabolism
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleMinireview

Alternative P450 Splicing Redirects Human Drug Metabolism

Andrew J. Annalora, Craig B. Marcus and Patrick L. Iversen
Drug Metabolism and Disposition April 1, 2017, 45 (4) 375-389; DOI: https://doi.org/10.1124/dmd.116.073254

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleMinireview

Alternative P450 Splicing Redirects Human Drug Metabolism

Andrew J. Annalora, Craig B. Marcus and Patrick L. Iversen
Drug Metabolism and Disposition April 1, 2017, 45 (4) 375-389; DOI: https://doi.org/10.1124/dmd.116.073254
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Meta-Analysis of Alternative Gene Splicing in the Cytochrome P450 Superfamily
    • Tissue-Specific Alternative Splicing of Cytochrome P450 Genes: Historical Perspective
    • Transformation-Sensitive Alternative Splicing in the Cytochrome P450 Superfamily
    • Trans-Splicing of Cytochrome P450 Gene Chimeras
    • SNP-Sensitive Alternative Splicing in the Cytochrome P450 Superfamily
    • Addressing Nontraditional P450 Function and Trafficking Events
    • Shaping an Improved Roadmap toward Precision Medicine
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Clinical Pharmacology of FDA-Approved Small Interfering RNAs
  • Unusual Biotransformation Reactions
  • Fifty years of AHR research in the pages of DMD
Show more Minireview

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics